<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2205245335
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Racitam
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVETIRACETAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        83.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; III" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – III
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Levetiracetam is an antiepileptic medicine (a medicine used to treat seizures in epilepsy). Racitam is used:</p><p>&bull;&nbsp; on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy. Epilepsy is a condition where the patients have repeated fits (seizures). Levetiracetam is used for the epilepsy form in which the fits initially affect only one side of the brain, but could thereafter extend to larger areas on both sides of the brain (partial onset seizure with or without secondary generalisation). Levetiracetam has been given to you by your doctor to reduce the number of fits.</p><p>&nbsp;</p><p>&bull;&nbsp; as an add-on to other antiepileptic medicines to treat:</p><p>&sect;&nbsp; partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age</p><p>&sect;&nbsp; myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy</p><p>&sect;&nbsp; primary generalised tonic-clonic seizures(major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take Racitam</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to levetiracetam, pyrrolidone derivatives or any of the other ingredients of this medicine (listed in Section 6).</p><p>Warnings and precautions</p><p>Talk to your doctor before taking Racitam</p><p>&bull;&nbsp; If you suffer from kidney problems, follow your doctor&rsquo;s instructions. He/she may decide if your dose should be adjusted.</p><p>&bull;&nbsp; If you notice any slow down in the growth or unexpected puberty development of your child, please contact your doctor.</p><p>&bull;&nbsp; A small number of people being treated with anti-epileptics such as Racitam have had thoughts of harming or killing themselves. If you have any symptoms of depression and/or suicidal ideation, please contact your doctor.</p><p>&bull;&nbsp; If you have a family or medical history of irregular heart rhythm (visible on an electrocardiogram), or if you have a disease and/or take a treatment that make(s) you prone to heartbeat irregularities or salt imbalances.</p><p>Tell your doctor or pharmacist if any of the following side effects gets serious or last longer than a few days:</p><p>&bull;&nbsp; Abnormal thoughts, feeling irritable or reacting more aggressively than usually, or if you or your family and friends notice important changes in mood or behaviour.</p><p>&bull;&nbsp; <u>Aggravation of epilepsy</u></p><p>Your seizures may rarely become worse or happen more often, mainly during the first month after the start of the treatment or increase of the dose. If you experience any of these new symptoms while taking Racitam, see a doctor as soon as possible.</p><p>&nbsp;</p><p>Children and adolescents</p><p>&bull;&nbsp; Racitam is not indicated in children and adolescents below 16 years on it&rsquo;s own (monotherapy)</p><p>Other medicines and Racitam</p><p>Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines.</p><p>Do not take macrogol (a drug used as laxative) for one hour before and one hour after taking levetiracetam as this may results in a reduction of its effect.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine. Levetiracetam can be used during pregnancy, only if after careful assessment it is considered necessary by your doctor.</p><p>You should not stop your treatment without discussing this with your doctor. A risk of birth defects for your unborn child cannot be completely excluded. Breast-feeding is not recommended during treatment.</p><p>Driving and using machines</p><p>Racitam may impair your ability to drive or operate any tools or machinery, as it may make you feel sleepy. This is more likely at the beginning of treatment or after an increase in the dose. You should not drive or use machines until it is established that your ability to perform such activities is not affected.</p><p><strong>Racitam contains methyl parahydroxybenzoate, propyl parahydroxybenzoate and maltitol </strong>Racitam oral solution includes methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed).</p><p>Racitam oral solution also contains maltitol. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Racitam must be taken twice a day, once in the morning and once in the evening, at about the same time each day.</p><p>Take the oral solution following your doctor&rsquo;s instructions.</p><p>&nbsp;</p><p>Monotherapy (from 16 years of age)</p><p><strong>Adults (&ge;18 years) and adolescents (from 16 years of age):</strong></p><p>Measure the appropriate dosage using the syringe included in the package for patients 4 years and above.</p><p>General dose: Racitam is taken twice daily, in two equally divided doses, each individual dose being measured between 5 ml (500mg) and 15 ml (1500mg).</p><p>When you will first start taking Racitam, your doctor will prescribe you a <strong>lower dose </strong>during 2 weeks before giving you the lowest general dose.</p><p>Add-on therapy</p><p><strong>Dose in adults and adolescents (12 to 17 years):</strong></p><p>Measure the appropriate dosage using the syringe included in the package for patients 4 years and above.</p><p>General dose: Racitam is taken twice daily, in two equally divided doses, each individual dose being measured between 5 ml (500mg) and 15 ml (1500mg).</p><p><strong>Dose in children 6 months and older :</strong></p><p>Your doctor will prescribe the most appropriate pharmaceutical form of Racitam according to the age, weight and dose.</p><p><strong>For children 6 months to 4 years, </strong>measure the appropriate dosage using the <strong>3 ml </strong>syringe included in the package.</p><p>Measure the appropriate dosage using the syringe included in the package for patients 4 years and above.</p><p>General dose: Racitam is taken twice daily, in two equally divided doses, each individual dose being measured between 0.1 ml (10mg) and 0.3 ml (30mg), per kg bodyweight of the child. (see table below for dose examples).</p><p>Dose in children 6 months and older:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>Starting dose:</p><p>0.1&nbsp;&nbsp;&nbsp;&nbsp; ml/kg&nbsp;&nbsp;&nbsp;&nbsp; twice daily</p></td><td style="vertical-align:top"><p>Maximum dose:</p><p>0.3 ml/kg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>6 kg</p></td><td style="vertical-align:top"><p>0.6 ml twice daily</p></td><td style="vertical-align:top"><p>1.8 ml twice daily</p></td></tr><tr><td style="vertical-align:top"><p>8 kg</p></td><td style="vertical-align:top"><p>0.8 ml twice daily</p></td><td style="vertical-align:top"><p>2.4 ml twice daily</p></td></tr><tr><td style="vertical-align:top"><p>10 kg</p></td><td style="vertical-align:top"><p>1 ml twice daily</p></td><td style="vertical-align:top"><p>3 ml twice daily</p></td></tr><tr><td style="vertical-align:top"><p>15 kg</p></td><td style="vertical-align:top"><p>1.5 ml twice daily</p></td><td style="vertical-align:top"><p>4.5 ml twice daily</p></td></tr><tr><td style="vertical-align:top"><p>20 kg</p></td><td style="vertical-align:top"><p>2 ml twice daily</p></td><td style="vertical-align:top"><p>6 ml twice daily</p></td></tr><tr><td style="vertical-align:top"><p>25 kg</p></td><td style="vertical-align:top"><p>2.5 ml twice daily</p></td><td style="vertical-align:top"><p>7.5 ml twice daily</p></td></tr><tr><td style="vertical-align:top"><p>From&nbsp;&nbsp;&nbsp; 50</p><p>kg</p></td><td style="vertical-align:top"><p>5 ml twice daily</p></td><td style="vertical-align:top"><p>15 ml twice daily</p></td></tr></tbody></table><p>&nbsp;</p><p>Dose in infants (1 month to less than 6 months):</p><p><strong>For infants 1 month to less than 6 months, </strong>measure the appropriate dosage using the syringe included in the package.</p><p>General dose: Racitam is taken twice daily, in two equally divided doses, each individual dose being measured between 0.07 ml (7mg) and 0.21 ml (21mg), per kg bodyweight of the infant. (see table below for dose examples).</p><p>Dose in infants (1 month to less than 6 months):</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>Starting dose:</p><p>0.07 ml/kg twice daily</p></td><td style="vertical-align:top"><p>Maximum dose:</p><p>0.21 ml/kg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>4 kg</p></td><td style="vertical-align:top"><p>0.3 ml twice daily</p></td><td style="vertical-align:top"><p>0.85 ml twice daily</p></td></tr><tr><td style="vertical-align:top"><p>5 kg</p></td><td style="vertical-align:top"><p>0.35 ml twice daily</p></td><td style="vertical-align:top"><p>1.05 ml twice daily</p></td></tr><tr><td style="vertical-align:top"><p>6 kg</p></td><td style="vertical-align:top"><p>0.45 ml twice daily</p></td><td style="vertical-align:top"><p>1.25 ml twice daily</p></td></tr><tr><td style="vertical-align:top"><p>7 kg</p></td><td style="vertical-align:top"><p>0.5 ml twice daily</p></td><td style="vertical-align:top"><p>1.5 ml twice daily</p></td></tr></tbody></table><p>&nbsp;</p><p>Method of administration:</p><p>After measuring the correct dosage with an appropriate syringe, Racitam oral solution may be diluted in a glass of water or baby&rsquo;s bottle. You may take Racitam with or without food. After oral administration the bitter taste of levetiracetam may be experienced.</p><p>Instructions for use:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
  path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="image2.png" o:spid="_x0000_s1350" type="#_x0000_t75"
  style='position:absolute;left:0;text-align:left;margin-left:108.7pt;
  margin-top:25.75pt;width:19.45pt;height:5.05pt;z-index:4;visibility:visible;
  mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
  mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><v:group id="_x0000_s1153" style='position:absolute;left:0;
  text-align:left;margin-left:135pt;margin-top:25.45pt;width:30.95pt;height:57.1pt;
  z-index:-251653120;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="2700,509" coordsize="619,1142">
  <v:line id="_x0000_s1154" style='position:absolute' from="3000,768" to="3000,877"
   strokecolor="#231f20" strokeweight="1.1973mm"/>
  <v:rect id="_x0000_s1155" style='position:absolute;left:2967;top:767;width:66;
   height:109' filled="f" strokecolor="#231f20" strokeweight=".1355mm"/>
  <v:line id="_x0000_s1156" style='position:absolute' from="3212,1252" to="3212,1527"
   strokecolor="#231f20" strokeweight=".1355mm"/>
  <v:line id="_x0000_s1157" style='position:absolute' from="2798,1246" to="2798,1537"
   strokecolor="#231f20" strokeweight=".1355mm"/>
  <v:shape id="_x0000_s1158" style='position:absolute;left:2797;top:1105;
   width:97;height:152' coordorigin="2797,1106" coordsize="97,152" path="m2797,1258r13,-62l2843,1144r32,-27l2894,1106e"
   filled="f" strokecolor="#231f20" strokeweight=".1355mm">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1159" style='position:absolute;left:2798;
   top:1523;width:413;height:123' coordorigin="2798,1524" coordsize="413,123"
   path="m3211,1524r-28,62l3131,1621r-71,22l3006,1647r-28,-1l2901,1631r-59,-31l2800,1542r-2,-17e"
   filled="f" strokecolor="#231f20" strokeweight=".1355mm">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1160" type="#_x0000_t75" style='position:absolute;
   left:2876;top:876;width:340;height:389'>
   <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png"
    o:title=""/>
  </v:shape><v:shape id="_x0000_s1161" type="#_x0000_t75" style='position:absolute;
   left:2700;top:508;width:619;height:263'>
   <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
    o:title=""/>
  </v:shape><w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td colspan="2">&nbsp;</td><td rowspan="3" style="vertical-align:top"><img width="41" height="78" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /></td></tr><tr><td>&nbsp;</td><td style="vertical-align:top"><img width="26" height="7" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image005.gif" /></td></tr><tr><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br /><!--[if gte vml 1]><v:group id="_x0000_s1162" style='position:absolute;left:0;
 text-align:left;margin-left:111.15pt;margin-top:131.05pt;width:63.65pt;
 height:54.55pt;z-index:251666432;mso-position-horizontal-relative:page'
 coordorigin="2223,2621" coordsize="1273,1091">
 <v:shape id="_x0000_s1163" style='position:absolute;left:3017;top:2897;
  width:475;height:459' coordorigin="3017,2898" coordsize="475,459" path="m3381,3357r-67,-21l3247,3281r-30,-42l3209,3234r-10,-9l3183,3217r-13,-12l3161,3201r-13,-7l3138,3189r-16,-21l3124,3156r5,-10l3133,3136r9,-5l3145,3127r-5,-5l3128,3111r-14,-14l3113,3087r2,-11l3124,3059r11,-6l3132,3041r-5,-11l3124,3022r-11,-2l3101,3014r-11,-5l3078,3003r-14,-7l3044,2982r-16,-17l3017,2942r5,-17l3034,2914r15,-4l3064,2911r21,6l3102,2924r5,3l3121,2908r13,l3147,2904r38,-6l3224,2911r52,26l3304,2949r68,39l3413,3046r27,41l3452,3108r15,14l3492,3147e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1164" style='position:absolute;left:3062;top:2931;
  width:24;height:47' coordorigin="3062,2932" coordsize="24,47" path="m3086,2932r-2,2l3074,2948r-9,17l3062,2979r9,-10l3076,2958r10,-19l3086,2932xe"
  fillcolor="#231f20" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1165" style='position:absolute;left:3062;top:2931;
  width:24;height:47' coordorigin="3062,2932" coordsize="24,47" path="m3062,2979r3,-14l3074,2948r10,-14l3086,2932r,7l3076,2958r-5,11l3062,2979xe"
  filled="f" strokecolor="#231f20" strokeweight=".07619mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1166" style='position:absolute;left:3174;top:2907;
  width:16;height:48' coordorigin="3174,2908" coordsize="16,48" path="m3190,2908r-3,18l3174,2956e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1167" style='position:absolute;left:3234;top:2940;
  width:36;height:37' coordorigin="3234,2941" coordsize="36,37" path="m3234,2978r8,-15l3252,2959r11,-8l3270,2941e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1168" style='position:absolute;left:3104;top:2924;
  width:225;height:67' coordorigin="3104,2925" coordsize="225,67" path="m3329,2979r-7,7l3306,2992r-11,l3224,2978r-65,-28l3136,2941r-12,-7l3104,2925e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1169" style='position:absolute;left:3122;top:3021;
  width:192;height:212' coordorigin="3122,3022" coordsize="192,212" path="m3122,3022r56,28l3218,3104r4,19l3236,3145r30,38l3283,3204r15,13l3306,3225r8,9e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1170" style='position:absolute;left:3230;top:3214;
  width:13;height:50' coordorigin="3230,3215" coordsize="13,50" path="m3243,3215r-6,12l3233,3241r-1,12l3230,3265e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:line id="_x0000_s1171" style='position:absolute' from="3202,3207"
  to="3202,3227" strokecolor="#231f20" strokeweight=".15417mm"/>
 <v:shape id="_x0000_s1172" style='position:absolute;left:3215;top:3214;
  width:10;height:23' coordorigin="3215,3215" coordsize="10,23" path="m3225,3215r-9,7l3215,3229r1,9e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1173" style='position:absolute;left:3135;top:3054;
  width:79;height:43' coordorigin="3135,3055" coordsize="79,43" path="m3135,3055r17,17l3164,3082r10,5l3191,3095r23,3e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1174" style='position:absolute;left:3143;top:3126;
  width:104;height:33' coordorigin="3143,3127" coordsize="104,33" path="m3143,3127r23,15l3191,3150r33,10l3247,3160e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1175" style='position:absolute;left:3170;top:3192;
  width:102;height:19' coordorigin="3170,3193" coordsize="102,19" path="m3170,3205r36,5l3234,3211r20,1l3261,3211r7,-10l3272,3193e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:line id="_x0000_s1176" style='position:absolute' from="3233,3162"
  to="3253,3167" strokecolor="#231f20" strokeweight=".1189mm"/>
 <v:shape id="_x0000_s1177" style='position:absolute;left:3184;top:3059;
  width:6;height:25' coordorigin="3184,3060" coordsize="6,25" path="m3185,3085r-1,-13l3190,3060e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1178" style='position:absolute;left:3200;top:3112;
  width:6;height:27' coordorigin="3200,3113" coordsize="6,27" path="m3200,3140r,-15l3206,3113e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1179" style='position:absolute;left:3174;top:3160;
  width:7;height:32' coordorigin="3174,3161" coordsize="7,32" path="m3179,3193r-5,-19l3181,3161e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1180" style='position:absolute;left:3217;top:3171;
  width:51;height:35' coordorigin="3217,3172" coordsize="51,35" path="m3224,3172r-4,6l3217,3183r1,13l3223,3200r33,7l3263,3202r4,-6l3268,3191r-7,-9l3254,3178r-30,-6xe"
  stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1181" style='position:absolute;left:3217;top:3171;
  width:51;height:35' coordorigin="3217,3172" coordsize="51,35" path="m3218,3196r,-5l3217,3183r1,-1l3220,3178r4,-6l3254,3178r7,4l3268,3191r-1,5l3263,3202r-7,5l3239,3203r-16,-3l3218,3196xe"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1182" style='position:absolute;left:3218;top:3173;
  width:12;height:27' coordorigin="3218,3174" coordsize="12,27" path="m3227,3174r-2,l3218,3184r,9l3222,3200r4,-7l3230,3177r-3,-3xe"
  fillcolor="#231f20" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1183" style='position:absolute;left:3015;top:2909;
  width:73;height:70' coordorigin="3015,2910" coordsize="73,70" path="m3032,2965r26,15l3071,2975r11,-17l3088,2943r-1,-15l3076,2923r-13,-8l3053,2910r-9,l3034,2911r-8,9l3020,2931r-5,9l3021,2952r3,7l3032,2965xe"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1184" style='position:absolute;left:2838;top:3240;
  width:76;height:91' coordorigin="2838,3241" coordsize="76,91" path="m2875,3241r-37,71l2877,3332r37,-70l2875,3241xe"
  fillcolor="#231f20" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1185" style='position:absolute;left:2838;top:3240;
  width:76;height:91' coordorigin="2838,3241" coordsize="76,91" path="m2914,3262r-37,70l2838,3312r37,-71l2914,3262xe"
  filled="f" strokecolor="#231f20" strokeweight=".45pt">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1186" style='position:absolute;left:2787;top:3208;
  width:159;height:217' coordorigin="2787,3209" coordsize="159,217" o:spt="100"
  adj="0,,0" path="m2862,3355r-38,-20l2787,3405r38,21l2862,3355t84,-76l2916,3209r-70,17l2946,3279e"
  fillcolor="#231f20" stroked="f">
  <v:stroke joinstyle="round"/>
  <v:formulas/>
  <v:path arrowok="t" o:connecttype="segments"/>
 </v:shape><v:shape id="_x0000_s1187" style='position:absolute;left:2787;top:3334;
  width:75;height:91' coordorigin="2787,3335" coordsize="75,91" path="m2787,3405r37,-70l2862,3355r-37,71l2787,3405xe"
  filled="f" strokecolor="#231f20" strokeweight=".45pt">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1188" style='position:absolute;left:2755;top:3387;
  width:99;height:69' coordorigin="2755,3388" coordsize="99,69" path="m2755,3388r30,69l2854,3440r-99,-52xe"
  fillcolor="#231f20" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1189" style='position:absolute;left:2921;top:3130;
  width:44;height:51' coordorigin="2921,3131" coordsize="44,51" path="m2965,3143r-20,39l2921,3170r21,-39e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1190" style='position:absolute;left:2963;top:2998;
  width:106;height:156' coordorigin="2963,2999" coordsize="106,156" path="m3069,2999r-82,156l2963,3142e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1191" style='position:absolute;left:3034;top:2816;
  width:111;height:108' coordorigin="3034,2817" coordsize="111,108" path="m3034,2899r42,-82l3145,2854r-37,71e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1192" style='position:absolute;left:2917;top:2852;
  width:141;height:280' coordorigin="2917,2853" coordsize="141,280" path="m2943,3133r-26,-13l3058,2853e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1193" style='position:absolute;left:3032;top:2784;
  width:165;height:92' coordorigin="3032,2785" coordsize="165,92" path="m3036,2785r161,85l3193,2877r-161,-85l3036,2785xe"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1194" style='position:absolute;left:2985;top:2988;
  width:70;height:41' coordorigin="2985,2989" coordsize="70,41" path="m2988,2989r67,35l3052,3030r-67,-35l2988,2989xe"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:line id="_x0000_s1195" style='position:absolute' from="2989,3098"
  to="2970,3134" strokecolor="#231f20" strokeweight=".1189mm"/>
 <v:line id="_x0000_s1196" style='position:absolute' from="3048,2984" to="2980,3114"
  strokecolor="#231f20" strokeweight=".1189mm"/>
 <v:line id="_x0000_s1197" style='position:absolute' from="2971,3130" to="2944,3116"
  strokecolor="#231f20" strokeweight=".1189mm"/>
 <v:line id="_x0000_s1198" style='position:absolute' from="2980,3109" to="2968,3103"
  strokecolor="#231f20" strokeweight=".1189mm"/>
 <v:line id="_x0000_s1199" style='position:absolute' from="3105,2874" to="3077,2860"
  strokecolor="#231f20" strokeweight=".1189mm"/>
 <v:line id="_x0000_s1200" style='position:absolute' from="3087,2911" to="3059,2897"
  strokecolor="#231f20" strokeweight=".1189mm"/>
 <v:line id="_x0000_s1201" style='position:absolute' from="3050,2977" to="3038,2971"
  strokecolor="#231f20" strokeweight=".1189mm"/>
 <v:line id="_x0000_s1202" style='position:absolute' from="3095,2891" to="3083,2884"
  strokecolor="#231f20" strokeweight=".1189mm"/>
 <v:line id="_x0000_s1203" style='position:absolute' from="3113,2859" to="3101,2853"
  strokecolor="#231f20" strokeweight=".1189mm"/>
 <v:line id="_x0000_s1204" style='position:absolute' from="3043,3000" to="3016,2985"
  strokecolor="#231f20" strokeweight=".1189mm"/>
 <v:line id="_x0000_s1205" style='position:absolute' from="3018,3044" to="2991,3029"
  strokecolor="#231f20" strokeweight=".1189mm"/>
 <v:line id="_x0000_s1206" style='position:absolute' from="2996,3089" to="2969,3075"
  strokecolor="#231f20" strokeweight=".1189mm"/>
 <v:line id="_x0000_s1207" style='position:absolute' from="3006,3066" to="2994,3060"
  strokecolor="#231f20" strokeweight=".1189mm"/>
 <v:line id="_x0000_s1208" style='position:absolute' from="3029,3023" to="3017,3017"
  strokecolor="#231f20" strokeweight=".1189mm"/>
 <v:shape id="_x0000_s1209" style='position:absolute;left:3169;top:2623;
  width:75;height:49' coordorigin="3169,2624" coordsize="75,49" path="m3176,2624r68,36l3237,2673r-68,-36l3176,2624xe"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1210" style='position:absolute;left:3094;top:2643;
  width:125;height:189' coordorigin="3094,2644" coordsize="125,189" path="m3183,2644r36,19l3130,2833r-36,-19l3183,2644xe"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:line id="_x0000_s1211" style='position:absolute' from="3021,2953"
  to="2997,2999" strokecolor="#231f20" strokeweight=".1189mm"/>
 <v:line id="_x0000_s1212" style='position:absolute' from="3124,2841" to="3086,2914"
  strokecolor="#231f20" strokeweight=".1189mm"/>
 <v:line id="_x0000_s1213" style='position:absolute' from="3090,2822" to="3044,2910"
  strokecolor="#231f20" strokeweight=".1189mm"/>
 <v:shape id="_x0000_s1214" style='position:absolute;left:2613;top:3549;
  width:189;height:101' coordorigin="2613,3550" coordsize="189,101" path="m2613,3550r52,50l2735,3637r55,14l2802,3651e"
  filled="f" strokecolor="#231f20" strokeweight=".07939mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1215" style='position:absolute;left:2651;top:3451;
  width:208;height:122' coordorigin="2651,3452" coordsize="208,122" path="m2665,3452r-7,1l2654,3455r-2,4l2651,3467r6,11l2701,3518r76,40l2836,3574r12,l2856,3570r3,-5l2859,3561r-1,-4e"
  filled="f" strokecolor="#231f20" strokeweight=".07939mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1216" style='position:absolute;left:2626;top:3452;
  width:245;height:142' coordorigin="2626,3453" coordsize="245,142" path="m2870,3587r-7,5l2852,3595r-15,-1l2774,3576r-76,-41l2645,3494r-19,-30l2632,3457r11,-4l2658,3453r85,26l2796,3509r54,40l2871,3580r-1,6l2870,3587xe"
  filled="f" strokecolor="#231f20" strokeweight=".07939mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1217" style='position:absolute;left:2741;top:3496;
  width:34;height:21' coordorigin="2741,3497" coordsize="34,21" path="m2774,3516r-1,2l2765,3516r-9,-5l2747,3506r-6,-5l2742,3499r1,-2l2751,3500r9,4l2768,3509r7,5l2774,3516xe"
  filled="f" strokecolor="#231f20" strokeweight=".07939mm">
  <v:path arrowok="t"/>
 </v:shape><v:line id="_x0000_s1218" style='position:absolute' from="2742,3501"
  to="2726,3532" strokecolor="#231f20" strokeweight=".07939mm"/>
 <v:line id="_x0000_s1219" style='position:absolute' from="2773,3516" to="2754,3551"
  strokecolor="#231f20" strokeweight=".07939mm"/>
 <v:line id="_x0000_s1220" style='position:absolute' from="2835,3595" to="2775,3709"
  strokecolor="#231f20" strokeweight=".07939mm"/>
 <v:shape id="_x0000_s1221" style='position:absolute;left:2582;top:3606;
  width:189;height:102' coordorigin="2582,3607" coordsize="189,102" path="m2582,3607r52,49l2705,3693r54,16l2771,3709e"
  filled="f" strokecolor="#231f20" strokeweight=".07939mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1222" style='position:absolute;left:2585;top:3538;
  width:109;height:86' coordorigin="2585,3539" coordsize="109,86" path="m2605,3539r-20,39l2674,3625r20,-39l2605,3539xe"
  stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1223" style='position:absolute;left:2624;top:3563;
  width:60;height:56' coordorigin="2624,3564" coordsize="60,56" path="m2649,3617r-22,-10l2624,3596r7,-15l2638,3570r10,-6l2657,3568r11,6l2676,3578r4,6l2684,3592r-2,9l2677,3610r-4,7l2663,3619r-6,1l2649,3617xe"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1224" style='position:absolute;left:2626;top:3565;
  width:23;height:40' coordorigin="2626,3566" coordsize="23,40" path="m2648,3566r-6,3l2632,3584r-5,10l2626,3606r12,-7l2646,3584r3,-15l2648,3566xe"
  fillcolor="#231f20" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1225" style='position:absolute;left:2546;top:3445;
  width:8;height:41' coordorigin="2546,3446" coordsize="8,41" path="m2546,3487r6,-12l2550,3466r,-11l2554,3446e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1226" style='position:absolute;left:2499;top:3423;
  width:141;height:127' coordorigin="2499,3424" coordsize="141,127" path="m2501,3424r-2,8l2503,3446r4,8l2520,3467r15,17l2549,3495r18,14l2580,3517r18,9l2615,3537r10,5l2640,3551e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1227" style='position:absolute;left:2337;top:3548;
  width:230;height:33' coordorigin="2337,3549" coordsize="230,33" path="m2567,3582r-26,-15l2523,3558r-12,-7l2497,3549r-14,1l2468,3555r-15,7l2433,3562r-40,-3l2371,3557r-15,-3l2347,3552r-10,-2e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1228" style='position:absolute;left:2355;top:3586;
  width:29;height:34' coordorigin="2355,3587" coordsize="29,34" path="m2384,3587r-6,10l2370,3607r-8,7l2355,3621e"
  filled="f" strokecolor="#231f20" strokeweight=".1238mm">
  <v:path arrowok="t"/>
 </v:shape><v:line id="_x0000_s1229" style='position:absolute' from="2405,3615"
  to="2395,3622" strokecolor="#231f20" strokeweight=".1189mm"/>
 <v:shape id="_x0000_s1230" style='position:absolute;left:2379;top:3601;
  width:11;height:16' coordorigin="2379,3602" coordsize="11,16" path="m2390,3602r,8l2386,3615r-7,3e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1231" style='position:absolute;left:2474;top:3554;
  width:65;height:33' coordorigin="2474,3555" coordsize="65,33" path="m2539,3588r-19,-3l2508,3582r-9,-5l2487,3569r-13,-14e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1232" style='position:absolute;left:2417;top:3560;
  width:70;height:55' coordorigin="2417,3561" coordsize="70,55" path="m2487,3616r-21,-9l2450,3594r-22,-17l2417,3561e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1233" style='position:absolute;left:2377;top:3559;
  width:46;height:73' coordorigin="2377,3560" coordsize="46,73" path="m2423,3633r-20,-21l2389,3594r-10,-13l2377,3576r3,-9l2384,3560e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:line id="_x0000_s1234" style='position:absolute' from="2423,3572"
  to="2410,3561" strokecolor="#231f20" strokeweight=".1189mm"/>
 <v:shape id="_x0000_s1235" style='position:absolute;left:2496;top:3553;
  width:14;height:15' coordorigin="2496,3554" coordsize="14,15" path="m2496,3569r9,-5l2510,3554e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1236" style='position:absolute;left:2452;top:3566;
  width:16;height:16' coordorigin="2452,3567" coordsize="16,16" path="m2452,3583r10,-6l2468,3567e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1237" style='position:absolute;left:2426;top:3605;
  width:21;height:16' coordorigin="2426,3606" coordsize="21,16" path="m2426,3622r16,-5l2447,3606e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1238" style='position:absolute;left:2382;top:3561;
  width:38;height:36' coordorigin="2382,3562" coordsize="38,36" path="m2396,3562r-9,l2384,3565r-2,5l2382,3577r20,19l2406,3598r9,-6l2417,3588r3,-5l2402,3565r-6,-3xe"
  stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1239" style='position:absolute;left:2382;top:3561;
  width:38;height:36' coordorigin="2382,3562" coordsize="38,36" path="m2406,3598r4,-3l2415,3592r1,-1l2417,3588r3,-5l2402,3565r-6,-3l2387,3562r-3,3l2382,3570r,7l2392,3587r10,9l2406,3598xe"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1240" style='position:absolute;left:2403;top:3578;
  width:15;height:17' coordorigin="2403,3579" coordsize="15,17" path="m2414,3579r-8,10l2403,3596r6,-2l2414,3590r4,-9l2417,3580r-3,-1xe"
  fillcolor="#231f20" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1241" style='position:absolute;left:2226;top:3391;
  width:457;height:258' coordorigin="2226,3392" coordsize="457,258" path="m2226,3563r61,43l2363,3622r17,-3l2388,3621r10,4l2411,3632r14,3l2432,3639r10,6l2450,3649r22,1l2479,3643r4,-8l2488,3628r,-8l2489,3616r6,1l2508,3620r15,3l2530,3619r7,-6l2545,3599r-2,-10l2553,3585r10,-1l2569,3582r7,7l2585,3594r8,5l2603,3604r11,6l2633,3618r18,3l2672,3617r9,-10l2683,3593r-4,-12l2672,3572r-14,-12l2645,3552r-4,-2l2647,3532r-6,-9l2638,3513r-14,-29l2598,3464r-41,-23l2536,3428r-58,-29l2454,3398r-33,1l2380,3399r-19,2l2344,3398r-28,-6e"
  filled="f" strokecolor="#231f20" strokeweight=".1189mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1242" style='position:absolute;left:2622;top:3505;
  width:44;height:45' coordorigin="2622,3506" coordsize="44,45" path="m2638,3506r-16,31l2650,3551r16,-30l2638,3506xe"
  stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:line id="_x0000_s1243" style='position:absolute' from="2643,3492"
  to="2619,3538" strokecolor="#231f20" strokeweight=".07939mm"/>
 <v:line id="_x0000_s1244" style='position:absolute' from="2589,3594" to="2581,3608"
  strokecolor="#231f20" strokeweight=".07939mm"/>
 <w:wrap anchorx="page"/>
</v:group><![endif]--><img width="87" height="75" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image006.gif" /><!--[if gte vml 1]><v:group
 id="_x0000_s1122" style='position:absolute;left:0;text-align:left;
 margin-left:244.35pt;margin-top:124.3pt;width:24.6pt;height:61.3pt;z-index:-252527616;
 mso-position-horizontal-relative:page' coordorigin="4887,2486" coordsize="492,1226">
 <v:line id="_x0000_s1123" style='position:absolute' from="5129,3135" to="5129,3222"
  strokecolor="#231f20" strokeweight=".877mm"/>
 <v:rect id="_x0000_s1124" style='position:absolute;left:5105;top:3134;width:48;
  height:87' filled="f" strokecolor="#231f20" strokeweight=".45pt"/>
 <v:shape id="_x0000_s1125" style='position:absolute;left:5066;top:3220;
  width:123;height:52' coordorigin="5066,3221" coordsize="123,52" path="m5189,3221r-123,1l5130,3273r59,-52xe"
  fillcolor="#231f20" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1126" style='position:absolute;left:5029;top:2919;
  width:207;height:39' coordorigin="5029,2920" coordsize="207,39" path="m5036,2920r-5,3l5029,2926r,4l5091,2956r30,3l5154,2958r68,-14l5236,2927r-2,-3l5231,2922e"
  filled="f" strokecolor="#231f20" strokeweight=".07939mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1127" style='position:absolute;left:5011;top:2907;
  width:242;height:65' coordorigin="5011,2908" coordsize="242,65" path="m5253,2940r-55,28l5141,2973r-32,-1l5035,2960r-24,-13l5014,2936r73,-26l5115,2908r34,l5224,2919r29,21xe"
  filled="f" strokecolor="#231f20" strokeweight=".07939mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1128" style='position:absolute;left:5116;top:2920;
  width:32;height:7' coordorigin="5116,2921" coordsize="32,7" path="m5148,2924r,2l5141,2928r-9,l5123,2928r-7,-2l5116,2924r,-2l5123,2921r9,l5141,2921r7,1l5148,2924xe"
  filled="f" strokecolor="#231f20" strokeweight=".07939mm">
  <v:path arrowok="t"/>
 </v:shape><v:line id="_x0000_s1129" style='position:absolute' from="5117,2926"
  to="5117,2957" strokecolor="#231f20" strokeweight=".07939mm"/>
 <v:line id="_x0000_s1130" style='position:absolute' from="5148,2924" to="5148,2960"
  strokecolor="#231f20" strokeweight=".07939mm"/>
 <v:line id="_x0000_s1131" style='position:absolute' from="5037,2960" to="5035,3077"
  strokecolor="#231f20" strokeweight=".07939mm"/>
 <v:line id="_x0000_s1132" style='position:absolute' from="5229,2961" to="5229,3076"
  strokecolor="#231f20" strokeweight=".07939mm"/>
 <v:shape id="_x0000_s1133" style='position:absolute;left:5035;top:3075;
  width:194;height:18' coordorigin="5035,3076" coordsize="194,18" path="m5035,3076r12,6l5063,3088r21,4l5108,3094r31,l5166,3092r22,-3l5206,3086r13,-5l5229,3076e"
  filled="f" strokecolor="#231f20" strokeweight=".07939mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1134" style='position:absolute;left:5036;top:3017;
  width:192;height:19' coordorigin="5036,3018" coordsize="192,19" path="m5036,3018r11,7l5064,3030r21,5l5109,3037r31,l5167,3035r22,-3l5206,3028r14,-5l5228,3018e"
  filled="f" strokecolor="#231f20" strokeweight=".07939mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1135" style='position:absolute;left:4999;top:3284;
  width:266;height:72' coordorigin="4999,3285" coordsize="266,72" path="m5265,3321r-77,33l5160,3357r-35,-1l5044,3347r-45,-24l5003,3314r72,-26l5104,3285r35,1l5220,3295r45,26xe"
  filled="f" strokecolor="#231f20" strokeweight=".07939mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1136" style='position:absolute;left:5000;top:3330;
  width:10;height:78' coordorigin="5000,3331" coordsize="10,78" path="m5003,3409r7,-12l5002,3387r7,-16l5000,3354r8,-13l5007,3336r-2,-5e"
  filled="f" strokecolor="#231f20" strokeweight=".45pt">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1137" style='position:absolute;left:5259;top:3329;
  width:10;height:76' coordorigin="5259,3330" coordsize="10,76" path="m5266,3406r-7,-15l5267,3379r-7,-19l5269,3346r-8,-10l5262,3333r1,-3e"
  filled="f" strokecolor="#231f20" strokeweight=".45pt">
  <v:path arrowok="t"/>
 </v:shape><v:line id="_x0000_s1138" style='position:absolute' from="5006,3331"
  to="5006,3443" strokecolor="#231f20" strokeweight=".07939mm"/>
 <v:line id="_x0000_s1139" style='position:absolute' from="5261,3334" to="5261,3442"
  strokecolor="#231f20" strokeweight=".07939mm"/>
 <v:shape id="_x0000_s1140" style='position:absolute;left:5006;top:3440;
  width:254;height:25' coordorigin="5006,3441" coordsize="254,25" path="m5006,3441r65,21l5120,3466r29,-1l5219,3457r31,-10l5260,3441e"
  filled="f" strokecolor="#231f20" strokeweight=".07939mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1141" style='position:absolute;left:5007;top:3384;
  width:253;height:27' coordorigin="5007,3385" coordsize="253,27" path="m5007,3387r65,21l5122,3412r29,-1l5221,3402r29,-10l5260,3385e"
  filled="f" strokecolor="#231f20" strokeweight=".07939mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1142" style='position:absolute;left:5006;top:3355;
  width:253;height:27' coordorigin="5006,3356" coordsize="253,27" path="m5006,3358r65,21l5121,3383r29,l5220,3374r30,-11l5259,3356e"
  filled="f" strokecolor="#231f20" strokeweight=".07939mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1143" style='position:absolute;left:5006;top:3410;
  width:253;height:26' coordorigin="5006,3411" coordsize="253,26" path="m5006,3412r65,21l5121,3437r29,l5220,3428r30,-11l5259,3411e"
  filled="f" strokecolor="#231f20" strokeweight=".07939mm">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1144" type="#_x0000_t75" style='position:absolute;
  left:5002;top:3286;width:261;height:68'>
  <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image007.png"
   o:title=""/>
 </v:shape><v:line id="_x0000_s1145" style='position:absolute' from="5133,2741"
  to="5133,2828" strokecolor="#231f20" strokeweight=".87772mm"/>
 <v:rect id="_x0000_s1146" style='position:absolute;left:5110;top:2740;width:47;
  height:87' filled="f" strokecolor="#231f20" strokeweight=".45pt"/>
 <v:shape id="_x0000_s1147" style='position:absolute;left:5070;top:2827;
  width:123;height:52' coordorigin="5070,2828" coordsize="123,52" path="m5193,2828r-123,l5135,2880r58,-52xe"
  fillcolor="#231f20" stroked="f">
  <v:path arrowok="t"/>
 </v:shape><v:shape id="_x0000_s1148" type="#_x0000_t75" style='position:absolute;
  left:5032;top:2486;width:284;height:197'>
  <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image008.png"
   o:title=""/>
 </v:shape><v:line id="_x0000_s1149" style='position:absolute' from="4891,3559"
  to="4891,3712" strokecolor="#231f20" strokeweight=".3pt"/>
 <v:shape id="_x0000_s1150" style='position:absolute;left:4890;top:3400;
  width:103;height:173' coordorigin="4890,3401" coordsize="103,173" path="m4890,3574r11,-62l4930,3457r45,-44l4993,3401e"
  filled="f" strokecolor="#231f20" strokeweight=".3pt">
  <v:path arrowok="t"/>
 </v:shape><v:line id="_x0000_s1151" style='position:absolute' from="5376,3563"
  to="5376,3707" strokecolor="#231f20" strokeweight=".3pt"/>
 <v:shape id="_x0000_s1152" style='position:absolute;left:5276;top:3404;
  width:100;height:174' coordorigin="5276,3405" coordsize="100,174" path="m5376,3579r-10,-62l5337,3462r-43,-45l5276,3405e"
  filled="f" strokecolor="#231f20" strokeweight=".3pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="34" height="83" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image009.gif" />Open the bottle: press the cap and turn it anticlockwise (figure 1)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Separate the adaptor from the syringe (figure 2). Insert the adaptor into the bottle neck (figure 3). Ensure it is well fixed.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="image7.png" o:spid="_x0000_s1349" type="#_x0000_t75" style='position:absolute;
  margin-left:93pt;margin-top:10pt;width:13.45pt;height:7.25pt;z-index:6;
  visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image010.png"
   o:title=""/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><v:shape id="image8.png" o:spid="_x0000_s1348" type="#_x0000_t75"
  style='position:absolute;margin-left:226.35pt;margin-top:14.1pt;width:11.95pt;
  height:7.5pt;z-index:7;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image011.png"
   o:title=""/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td style="vertical-align:top"><img width="18" height="10" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image012.gif" /></td><td>&nbsp;</td><td style="vertical-align:top"><img width="16" height="10" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image013.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take the syringe and put it in the adaptor opening (figure 4). Turn the bottle upside down (figure 5).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fill the syringe with a small amount of solution by pulling the piston down (figure 5A), then push the piston upward in order to remove any possible bubble (figure 5B). Pull the piston down to the graduation mark corresponding to the quantity in milliliters (ml) prescribed by your doctor (figure 5C).</p><p><!--[if gte vml 1]><v:shape id="image16.png"
 o:spid="_x0000_i1031" type="#_x0000_t75" style='width:98.25pt;height:75.75pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image024.png"
  o:title=""/>
</v:shape><![endif]--><img width="131" height="101" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image025.gif" />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:shape id="image17.png"
 o:spid="_x0000_i1030" type="#_x0000_t75" style='width:57pt;height:77.25pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image026.png"
  o:title=""/>
</v:shape><![endif]--><img width="76" height="103" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image027.gif" />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:shape id="image18.png" o:spid="_x0000_i1029"
 type="#_x0000_t75" style='width:55.5pt;height:76.5pt;visibility:visible;
 mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image028.png"
  o:title=""/>
</v:shape><![endif]--><img width="74" height="102" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image029.gif" /></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turn the bottle the right way up (figure 6A). Remove the syringe from the adaptor (figure 6B).</p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:group
  id="_x0000_s1245" style='position:absolute;margin-left:71.65pt;margin-top:16.7pt;
  width:40.65pt;height:76.15pt;z-index:-251644928;mso-wrap-distance-left:0;
  mso-wrap-distance-right:0;mso-position-horizontal-relative:page'
  coordorigin="1433,334" coordsize="813,1523">
  <v:shape id="_x0000_s1246" style='position:absolute;left:1777;top:1013;
   width:85;height:111' coordorigin="1777,1013" coordsize="85,111" path="m1777,1124r34,-72l1843,1025r19,-12e"
   filled="f" strokecolor="#231f20" strokeweight=".45pt">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1247" style='position:absolute;left:1775;
   top:1124;width:2;height:17' coordorigin="1775,1124" coordsize="2,17" path="m1775,1141r,-6l1776,1129r1,-5e"
   filled="f" strokecolor="#231f20" strokeweight=".45pt">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1248" style='position:absolute;left:1870;
   top:947;width:8;height:64' coordorigin="1870,947" coordsize="8,64" path="m1872,1011r6,-10l1871,992r6,-12l1870,966r6,-11l1875,951r-1,-4e"
   filled="f" strokecolor="#231f20" strokeweight=".45pt">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1249" style='position:absolute;left:2082;
   top:946;width:8;height:63' coordorigin="2082,946" coordsize="8,63" path="m2088,1009r-6,-13l2089,986r-6,-15l2090,960r-6,-9l2085,946e"
   filled="f" strokecolor="#231f20" strokeweight=".45pt">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1250" style='position:absolute;left:1867;
   top:903;width:224;height:42' coordorigin="1867,903" coordsize="224,42"
   path="m1875,903r-5,4l1867,911r,4l1926,942r29,3l1989,944r75,-10l2091,912r-2,-4l2086,906e"
   filled="f" strokecolor="#231f20" strokeweight=".07939mm">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1251" style='position:absolute;left:1846;
   top:891;width:263;height:69' coordorigin="1846,891" coordsize="263,69"
   path="m2109,926r-77,32l2003,960r-35,l1888,951r-42,-25l1850,918r73,-25l1952,891r35,l2067,901r42,25xe"
   filled="f" strokecolor="#231f20" strokeweight=".07939mm">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1252" style='position:absolute;left:1962;
   top:905;width:34;height:7' coordorigin="1962,905" coordsize="34,7" path="m1996,908r,2l1988,912r-9,l1970,912r-8,-2l1962,908r,-2l1970,905r9,l1988,905r8,1l1996,908xe"
   filled="f" strokecolor="#231f20" strokeweight=".07939mm">
   <v:path arrowok="t"/>
  </v:shape><v:line id="_x0000_s1253" style='position:absolute' from="1963,910"
   to="1963,943" strokecolor="#231f20" strokeweight=".07939mm"/>
  <v:line id="_x0000_s1254" style='position:absolute' from="1996,908" to="1996,947"
   strokecolor="#231f20" strokeweight=".07939mm"/>
  <v:line id="_x0000_s1255" style='position:absolute' from="1876,947" to="1874,1039"
   strokecolor="#231f20" strokeweight=".07939mm"/>
  <v:line id="_x0000_s1256" style='position:absolute' from="2084,948" to="2084,1038"
   strokecolor="#231f20" strokeweight=".07939mm"/>
  <v:shape id="_x0000_s1257" style='position:absolute;left:1874;top:1037;
   width:203;height:20' coordorigin="1874,1037" coordsize="203,20" path="m1874,1037r71,19l1970,1057r28,l2024,1055r21,-4l2063,1047r14,-5e"
   filled="f" strokecolor="#231f20" strokeweight=".07939mm">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1258" style='position:absolute;left:1875;
   top:992;width:202;height:21' coordorigin="1875,992" coordsize="202,21"
   path="m1875,992r71,20l1971,1013r29,l2025,1010r21,-4l2064,1002r13,-6e"
   filled="f" strokecolor="#231f20" strokeweight=".07939mm">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1259" style='position:absolute;left:1875;
   top:969;width:201;height:21' coordorigin="1875,969" coordsize="201,21"
   path="m1875,969r70,19l1971,990r28,-1l2024,987r22,-4l2063,978r13,-6e"
   filled="f" strokecolor="#231f20" strokeweight=".07939mm">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1260" style='position:absolute;left:1875;
   top:1013;width:201;height:21' coordorigin="1875,1013" coordsize="201,21"
   path="m1875,1013r70,20l1971,1034r28,-1l2024,1031r22,-4l2063,1022r13,-5e"
   filled="f" strokecolor="#231f20" strokeweight=".07939mm">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1261" style='position:absolute;left:1969;
   top:887;width:20;height:36' coordorigin="1969,887" coordsize="20,36" path="m1989,887r,36l1969,923r,-36e"
   filled="f" strokecolor="#231f20" strokeweight=".1189mm">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1262" style='position:absolute;left:1950;
   top:625;width:57;height:266' coordorigin="1950,625" coordsize="57,266"
   path="m1971,891r-21,l1950,625r57,l2007,891r-20,e" filled="f" strokecolor="#231f20"
   strokeweight=".1189mm">
   <v:path arrowok="t"/>
  </v:shape><v:line id="_x0000_s1263" style='position:absolute' from="1910,621"
   to="2049,621" strokecolor="#231f20"/>
  <v:rect id="_x0000_s1264" style='position:absolute;left:1966;top:350;width:29;
   height:268' filled="f" strokecolor="#231f20" strokeweight=".1189mm"/>
  <v:rect id="_x0000_s1265" style='position:absolute;left:1963;top:625;width:32;
   height:32' filled="f" strokecolor="#231f20" strokeweight=".1189mm"/>
  <v:line id="_x0000_s1266" style='position:absolute' from="1948,659" to="2010,659"
   strokecolor="#231f20" strokeweight=".24306mm"/>
  <v:line id="_x0000_s1267" style='position:absolute' from="1989,626" to="1989,879"
   strokecolor="#231f20" strokeweight=".1189mm"/>
  <v:line id="_x0000_s1268" style='position:absolute' from="1992,878" to="1966,878"
   strokecolor="#231f20" strokeweight=".1189mm"/>
  <v:line id="_x0000_s1269" style='position:absolute' from="1988,627" to="1965,627"
   strokecolor="#231f20" strokeweight=".1189mm"/>
  <v:line id="_x0000_s1270" style='position:absolute' from="1988,843" to="1965,843"
   strokecolor="#231f20" strokeweight=".1189mm"/>
  <v:line id="_x0000_s1271" style='position:absolute' from="1987,860" to="1978,860"
   strokecolor="#231f20" strokeweight=".1189mm"/>
  <v:line id="_x0000_s1272" style='position:absolute' from="1988,654" to="1965,654"
   strokecolor="#231f20" strokeweight=".1189mm"/>
  <v:line id="_x0000_s1273" style='position:absolute' from="1989,686" to="1966,686"
   strokecolor="#231f20" strokeweight=".1189mm"/>
  <v:line id="_x0000_s1274" style='position:absolute' from="1988,725" to="1965,725"
   strokecolor="#231f20" strokeweight=".1189mm"/>
  <v:line id="_x0000_s1275" style='position:absolute' from="1989,764" to="1966,764"
   strokecolor="#231f20" strokeweight=".1189mm"/>
  <v:line id="_x0000_s1276" style='position:absolute' from="1988,803" to="1965,803"
   strokecolor="#231f20" strokeweight=".1189mm"/>
  <v:line id="_x0000_s1277" style='position:absolute' from="1987,785" to="1978,785"
   strokecolor="#231f20" strokeweight=".1189mm"/>
  <v:line id="_x0000_s1278" style='position:absolute' from="1987,822" to="1978,822"
   strokecolor="#231f20" strokeweight=".1189mm"/>
  <v:line id="_x0000_s1279" style='position:absolute' from="1987,745" to="1978,745"
   strokecolor="#231f20" strokeweight=".1189mm"/>
  <v:line id="_x0000_s1280" style='position:absolute' from="1987,707" to="1978,707"
   strokecolor="#231f20" strokeweight=".1189mm"/>
  <v:line id="_x0000_s1281" style='position:absolute' from="1987,669" to="1978,669"
   strokecolor="#231f20" strokeweight=".1189mm"/>
  <v:line id="_x0000_s1282" style='position:absolute' from="1988,641" to="1978,641"
   strokecolor="#231f20" strokeweight=".1189mm"/>
  <v:line id="_x0000_s1283" style='position:absolute' from="1944,345" to="2019,345"
   strokecolor="#231f20" strokeweight=".40394mm"/>
  <v:line id="_x0000_s1284" style='position:absolute' from="2186,1134" to="2186,1515"
   strokecolor="#231f20" strokeweight=".45pt"/>
  <v:shape id="_x0000_s1285" style='position:absolute;left:2095;top:1007;
   width:91;height:131' coordorigin="2095,1007" coordsize="91,131" path="m2186,1138r-14,-58l2132,1032r-18,-13l2095,1007e"
   filled="f" strokecolor="#231f20" strokeweight=".45pt">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1286" style='position:absolute;left:1819;
   top:1507;width:368;height:107' coordorigin="1819,1507" coordsize="368,107"
   path="m2187,1507r-31,56l2101,1594r-75,18l1998,1614r-26,-1l1902,1605r-70,-25l1819,1572e"
   filled="f" strokecolor="#231f20" strokeweight=".45pt">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1287" style='position:absolute;left:1812;
   top:1244;width:126;height:65' coordorigin="1812,1244" coordsize="126,65"
   path="m1812,1293r5,2l1823,1298r57,11l1893,1308r16,l1922,1284r6,-20l1935,1250r3,-6e"
   filled="f" strokecolor="#231f20" strokeweight=".45pt">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1288" style='position:absolute;left:1787;
   top:1613;width:139;height:232' coordorigin="1787,1613" coordsize="139,232"
   path="m1787,1845r64,-146l1858,1678r38,-38l1914,1623r12,-10e" filled="f"
   strokecolor="#231f20" strokeweight=".45pt">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1289" style='position:absolute;left:1864;
   top:1198;width:78;height:249' coordorigin="1864,1198" coordsize="78,249"
   path="m1872,1202r12,-4l1896,1199r10,1l1940,1253r2,26l1931,1329r-43,85l1865,1447r-1,e"
   filled="f" strokecolor="#231f20" strokeweight=".45pt">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1290" style='position:absolute;left:1776;
   top:1201;width:98;height:117' coordorigin="1776,1201" coordsize="98,117"
   path="m1776,1318r1,l1829,1254r29,-42l1868,1206r6,-5e" filled="f"
   strokecolor="#231f20" strokeweight=".45pt">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1291" style='position:absolute;left:1752;
   top:1130;width:9;height:11' coordorigin="1752,1130" coordsize="9,11" path="m1752,1141r3,-4l1758,1134r3,-4e"
   filled="f" strokecolor="#231f20" strokeweight=".45pt">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1292" style='position:absolute;left:1437;
   top:1142;width:315;height:710' coordorigin="1437,1142" coordsize="315,710"
   path="m1437,1852r33,-60l1504,1736r14,-34l1531,1627r12,-31l1561,1563r4,-18l1568,1510r9,-42l1591,1441r13,-24l1623,1381r29,-62l1658,1302r14,-42l1675,1250r13,-27l1709,1193r18,-20l1739,1158r13,-16e"
   filled="f" strokecolor="#231f20" strokeweight=".45pt">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1293" style='position:absolute;left:1803;
   top:1279;width:99;height:29' coordorigin="1803,1279" coordsize="99,29"
   path="m1814,1279r-9,7l1804,1289r-1,4l1815,1294r10,3l1849,1301r25,5l1893,1308r8,-2l1902,1301r-7,-5l1876,1288r-20,-5l1835,1280r-21,-1xe"
   fillcolor="#231f20" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1294" style='position:absolute;left:1632;
   top:1316;width:146;height:187' coordorigin="1632,1316" coordsize="146,187"
   path="m1632,1503r3,-7l1644,1481r10,-12l1662,1458r11,-7l1684,1444r12,-9l1707,1428r36,-44l1750,1372r4,-7l1756,1356r5,-10l1769,1334r5,-10l1777,1319r1,-3e"
   filled="f" strokecolor="#231f20" strokeweight=".45pt">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1295" style='position:absolute;left:1771;
   top:1457;width:85;height:208' coordorigin="1771,1457" coordsize="85,208"
   path="m1856,1457r-10,18l1836,1491r-12,17l1816,1523r-4,20l1808,1564r10,18l1821,1604r-3,25l1805,1645r-34,20e"
   filled="f" strokecolor="#231f20" strokeweight=".45pt">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1296" style='position:absolute;left:1790;
   top:1360;width:33;height:7' coordorigin="1790,1360" coordsize="33,7" path="m1823,1360r-13,7l1790,1366e"
   filled="f" strokecolor="#231f20" strokeweight=".45pt">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1297" style='position:absolute;left:1789;
   top:1373;width:34;height:7' coordorigin="1789,1373" coordsize="34,7" path="m1823,1373r-14,7l1789,1379e"
   filled="f" strokecolor="#231f20" strokeweight=".45pt">
   <v:path arrowok="t"/>
  </v:shape><v:line id="_x0000_s1298" style='position:absolute' from="1815,1295"
   to="1803,1288" strokecolor="#231f20" strokeweight=".36pt"/>
  <v:shape id="_x0000_s1299" style='position:absolute;left:2183;top:1292;
   width:58;height:78' coordorigin="2183,1292" coordsize="58,78" path="m2183,1292r13,1l2213,1294r20,12l2241,1325r-7,19l2216,1357r-12,8l2194,1369r-3,1e"
   filled="f" strokecolor="#231f20" strokeweight=".36pt">
   <v:path arrowok="t"/>
  </v:shape><v:line id="_x0000_s1300" style='position:absolute' from="1854,1461"
   to="1868,1443" strokecolor="#231f20" strokeweight=".45pt"/>
  <v:line id="_x0000_s1301" style='position:absolute' from="1760,1132" to="1781,1112"
   strokecolor="#231f20" strokeweight=".45pt"/>
  <v:shape id="_x0000_s1302" style='position:absolute;left:2182;top:1194;
   width:41;height:73' coordorigin="2182,1194" coordsize="41,73" path="m2182,1194r7,1l2195,1195r21,12l2223,1226r-7,19l2198,1258r-11,8l2186,1267e"
   filled="f" strokecolor="#231f20" strokeweight=".36pt">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1303" style='position:absolute;left:2180;
   top:1091;width:41;height:72' coordorigin="2180,1091" coordsize="41,72"
   path="m2180,1091r7,l2193,1092r20,11l2221,1123r-7,18l2196,1154r-11,9l2184,1163e"
   filled="f" strokecolor="#231f20" strokeweight=".36pt">
   <v:path arrowok="t"/>
  </v:shape><v:line id="_x0000_s1304" style='position:absolute' from="1776,1128"
   to="1776,1322" strokecolor="#231f20" strokeweight=".45pt"/>
  <v:shape id="_x0000_s1305" type="#_x0000_t75" style='position:absolute;
   left:1725;top:640;width:112;height:153'>
   <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image030.png"
    o:title=""/>
  </v:shape><v:shape id="_x0000_s1306" type="#_x0000_t75" style='position:absolute;
   left:1470;top:624;width:184;height:184'>
   <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image031.png"
    o:title=""/>
  </v:shape><w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><v:group id="_x0000_s1307" style='position:absolute;margin-left:124.9pt;
  margin-top:18.35pt;width:63.4pt;height:68.7pt;z-index:-251643904;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="2498,367" coordsize="1268,1374">
  <v:shape id="_x0000_s1308" type="#_x0000_t75" style='position:absolute;
   left:2814;top:1287;width:489;height:453'>
   <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image032.png"
    o:title=""/>
  </v:shape><v:shape id="_x0000_s1309" type="#_x0000_t75" style='position:absolute;
   left:2714;top:886;width:218;height:308'>
   <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image033.png"
    o:title=""/>
  </v:shape><v:shape id="_x0000_s1310" style='position:absolute;left:2982;
   top:1004;width:101;height:90' coordorigin="2982,1004" coordsize="101,90"
   path="m3022,1092r46,2l3081,1079r2,-31l3081,1023r-11,-19l3051,1004r-23,l3011,1004r-12,6l2986,1020r-4,17l2982,1056r,15l2998,1083r9,7l3022,1092xe"
   filled="f" strokecolor="#231f20" strokeweight=".1242mm">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1311" style='position:absolute;left:3039;
   top:1168;width:30;height:49' coordorigin="3039,1168" coordsize="30,49"
   path="m3069,1168r,49l3039,1217r,-49e" filled="f" strokecolor="#231f20"
   strokeweight=".1242mm">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1312" style='position:absolute;left:3066;
   top:1115;width:31;height:51' coordorigin="3066,1115" coordsize="31,51"
   path="m3096,1115r1,51l3066,1166e" filled="f" strokecolor="#231f20"
   strokeweight=".1242mm">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1313" style='position:absolute;left:3009;
   top:784;width:87;height:215' coordorigin="3009,784" coordsize="87,215"
   path="m3009,999r,-215l3096,784r,189e" filled="f" strokecolor="#231f20"
   strokeweight=".1242mm">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1314" style='position:absolute;left:3009;
   top:1095;width:32;height:71' coordorigin="3009,1095" coordsize="32,71"
   path="m3041,1166r-32,l3009,1095e" filled="f" strokecolor="#231f20"
   strokeweight=".1242mm">
   <v:path arrowok="t"/>
  </v:shape><v:line id="_x0000_s1315" style='position:absolute' from="2947,778"
   to="3159,778" strokecolor="#231f20" strokeweight=".28292mm"/>
  <v:shape id="_x0000_s1316" style='position:absolute;left:3024;top:387;
   width:47;height:386' coordorigin="3024,387" coordsize="47,386" path="m3024,387r46,l3071,773r-46,l3024,387xe"
   filled="f" strokecolor="#231f20" strokeweight=".1242mm">
   <v:path arrowok="t"/>
  </v:shape><v:line id="_x0000_s1317" style='position:absolute' from="3008,379"
   to="3089,379" strokecolor="#231f20" strokeweight=".44203mm"/>
  <v:shape id="_x0000_s1318" style='position:absolute;left:3028;top:784;
   width:50;height:45' coordorigin="3028,784" coordsize="50,45" path="m3029,829r49,l3078,784r-50,l3029,829xe"
   filled="f" strokecolor="#231f20" strokeweight=".1242mm">
   <v:path arrowok="t"/>
  </v:shape><v:line id="_x0000_s1319" style='position:absolute' from="3007,833"
   to="3099,833" strokecolor="#231f20" strokeweight=".28964mm"/>
  <v:line id="_x0000_s1320" style='position:absolute' from="3069,1107" to="3069,1150"
   strokecolor="#231f20" strokeweight=".1242mm"/>
  <v:line id="_x0000_s1321" style='position:absolute' from="3068,784" to="3068,986"
   strokecolor="#231f20" strokeweight=".1242mm"/>
  <v:line id="_x0000_s1322" style='position:absolute' from="3068,1149" to="3033,1149"
   strokecolor="#231f20" strokeweight=".1242mm"/>
  <v:line id="_x0000_s1323" style='position:absolute' from="3066,786" to="3031,786"
   strokecolor="#231f20" strokeweight=".1242mm"/>
  <v:line id="_x0000_s1324" style='position:absolute' from="3066,1123" to="3051,1123"
   strokecolor="#231f20" strokeweight=".1242mm"/>
  <v:line id="_x0000_s1325" style='position:absolute' from="3066,826" to="3031,826"
   strokecolor="#231f20" strokeweight=".1242mm"/>
  <v:line id="_x0000_s1326" style='position:absolute' from="3068,871" to="3033,871"
   strokecolor="#231f20" strokeweight=".1242mm"/>
  <v:line id="_x0000_s1327" style='position:absolute' from="3066,928" to="3031,928"
   strokecolor="#231f20" strokeweight=".1242mm"/>
  <v:line id="_x0000_s1328" style='position:absolute' from="3069,984" to="3033,984"
   strokecolor="#231f20" strokeweight=".1242mm"/>
  <v:line id="_x0000_s1329" style='position:absolute' from="3066,956" to="3051,956"
   strokecolor="#231f20" strokeweight=".1242mm"/>
  <v:line id="_x0000_s1330" style='position:absolute' from="3066,902" to="3051,902"
   strokecolor="#231f20" strokeweight=".1242mm"/>
  <v:line id="_x0000_s1331" style='position:absolute' from="3065,847" to="3051,847"
   strokecolor="#231f20" strokeweight=".1242mm"/>
  <v:line id="_x0000_s1332" style='position:absolute' from="3067,807" to="3052,807"
   strokecolor="#231f20" strokeweight=".1242mm"/>
  <v:shape id="_x0000_s1333" style='position:absolute;left:3065;top:1007;
   width:18;height:87' coordorigin="3066,1007" coordsize="18,87" path="m3076,1007r-4,5l3066,1040r1,31l3076,1094r8,-22l3084,1053r-2,-35l3076,1007xe"
   fillcolor="#231f20" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:line id="_x0000_s1334" style='position:absolute' from="3115,962"
   to="3131,988" strokecolor="#231f20" strokeweight=".1242mm"/>
  <v:shape id="_x0000_s1335" style='position:absolute;left:3197;top:906;
   width:13;height:75' coordorigin="3197,906" coordsize="13,75" path="m3197,906r9,25l3210,981e"
   filled="f" strokecolor="#231f20" strokeweight=".1242mm">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1336" style='position:absolute;left:3305;
   top:893;width:23;height:75' coordorigin="3305,893" coordsize="23,75" path="m3305,968r,-26l3316,929r10,-18l3328,893e"
   filled="f" strokecolor="#231f20" strokeweight=".1242mm">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1337" style='position:absolute;left:3094;
   top:903;width:340;height:88' coordorigin="3094,903" coordsize="340,88"
   path="m3434,903r-5,15l3412,938r-15,8l3366,957r-40,15l3293,977r-42,7l3223,986r-37,l3148,989r-20,l3094,991e"
   filled="f" strokecolor="#231f20" strokeweight=".1242mm">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1338" style='position:absolute;left:3175;
   top:1103;width:419;height:150' coordorigin="3175,1103" coordsize="419,150"
   path="m3175,1105r58,-2l3272,1103r27,l3324,1112r24,13l3367,1147r19,24l3421,1189r70,29l3530,1235r29,7l3576,1248r18,5e"
   filled="f" strokecolor="#231f20" strokeweight=".1242mm">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1339" type="#_x0000_t75" style='position:absolute;
   left:3224;top:1105;width:289;height:253'>
   <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image034.png"
    o:title=""/>
  </v:shape><v:shape id="_x0000_s1340" style='position:absolute;left:2979;
   top:875;width:783;height:513' coordorigin="2979,875" coordsize="783,513"
   path="m3762,1371r-40,12l3687,1388r-25,l3629,1388r-33,-7l3533,1363r-44,-15l3463,1328r-14,-2l3428,1323r-27,l3375,1315r-14,2l3339,1317r-17,l3285,1301r-5,-19l3280,1266r-2,-17l3285,1237r2,-8l3276,1226r-24,-6l3225,1211r-9,-13l3210,1182r,-30l3221,1138r-13,-15l3193,1112r-9,-9l3168,1109r-20,l3129,1110r-20,l3085,1110r-37,-3l3015,1096r-31,-24l2979,1046r9,-23l3004,1006r21,-9l3058,990r27,-2l3094,988r6,-35l3116,944r15,-15l3179,895r60,-11l3328,882r45,-4l3399,875r28,l3454,875r39,7l3535,900r53,31l3654,966r32,20l3715,995r47,14e"
   filled="f" strokecolor="#231f20" strokeweight=".1242mm">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1341" style='position:absolute;left:3183;
   top:1008;width:29;height:72' coordorigin="3183,1008" coordsize="29,72"
   path="m3185,1008r-2,4l3186,1014r16,12l3206,1042r-4,18l3192,1077r5,3l3199,1077r9,-16l3212,1043r-3,-16l3196,1013r-11,-5xe"
   fillcolor="#231f20" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1342" style='position:absolute;left:3168;
   top:1017;width:24;height:65' coordorigin="3168,1017" coordsize="24,65"
   path="m3170,1017r-2,5l3172,1023r12,13l3185,1052r-7,17l3171,1079r6,3l3179,1079r8,-15l3192,1047r-3,-16l3175,1019r-5,-2xe"
   fillcolor="#231f20" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1343" style='position:absolute;left:2751;
   top:642;width:74;height:150' coordorigin="2751,642" coordsize="74,150"
   path="m2760,642r-6,l2751,645r,143l2754,792r38,l2814,786r11,-10l2767,776r,-56l2825,720r-3,-4l2816,712r-9,-1l2807,710r11,-4l2819,705r-52,l2767,658r52,l2819,657r-17,-13l2760,642xe"
   fillcolor="#231f20" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1344" style='position:absolute;left:2807;
   top:720;width:29;height:56' coordorigin="2807,720" coordsize="29,56" path="m2825,720r-17,l2819,731r,33l2807,776r18,l2829,772r7,-21l2836,738r-3,-9l2827,722r-2,-2xe"
   fillcolor="#231f20" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1345" style='position:absolute;left:2799;
   top:658;width:26;height:47' coordorigin="2799,658" coordsize="26,47" path="m2819,658r-19,l2809,667r,28l2799,705r20,l2825,693r,-15l2819,658xe"
   fillcolor="#231f20" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="_x0000_s1346" type="#_x0000_t75" style='position:absolute;
   left:2498;top:619;width:184;height:185'>
   <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image035.png"
    o:title=""/>
  </v:shape><w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td rowspan="2" style="vertical-align:top"><img width="56" height="102" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image036.gif" /></td><td>&nbsp;</td><td style="vertical-align:top"><img width="85" height="92" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image037.gif" /></td></tr><tr><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Empty the contents of the syringe in a glass of water or baby&rsquo;s bottle by pushing the piston to the bottom of the syringe (figure 7).</p><p><!--[if gte vml 1]><v:shape id="image25.png"
 o:spid="_x0000_i1028" type="#_x0000_t75" style='width:48pt;height:39pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image038.png"
  o:title=""/>
</v:shape><![endif]--><img width="64" height="52" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image039.jpg" /></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drink the whole contents of the glass/baby&rsquo;s bottle.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Close the bottle with the plastic screw cap.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wash the syringe with water only (figure 8).</p><p><!--[if gte vml 1]><o:wrapblock><v:shape id="image26.png"
  o:spid="_x0000_s1347" type="#_x0000_t75" style='position:absolute;
  margin-left:106.5pt;margin-top:15.2pt;width:51.75pt;height:54.25pt;z-index:15;
  visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image040.png"
   o:title=""/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="69" height="72" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image041.jpg" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>Duration of treatment:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Racitam is used as a chronic treatment. You should continue Racitam treatment for as long as your doctor has told you.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not stop your treatment without your doctor&rsquo;s advice as this could increase your seizures.</p><p>If you take more Racitam than you should</p><p>The possible side effects of an overdose of Racitam are sleepiness, agitation, aggression, decrease of alertness, inhibition of breathing and coma.</p><p>Contact your doctor if you took more Racitam than you should. Your doctor will establish the best possible treatment of overdose.</p><p>If you forget to take Racitam:</p><p>Contact your doctor if you have missed one or more doses. Do not take a double dose to make up for a forgotten dose. <strong>If you stop taking Racitam:</strong></p><p>If stopping treatment, Racitam should be discontinued gradually to avoid an increase of seizures. Should your doctor decide to stop your Racitam treatment, he/she will instruct you about the gradual withdrawal of Racitam.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Tell your doctor immediately, or go to your nearest emergency department, if you experience:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; weakness, feel light-headed or dizzy or have difficulty breathing, as these may be signs of a serious allergic (anaphylactic) reaction</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips, tongue and throat (Quincke&rsquo;s oedema)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flu-like symptoms and a rash on the face followed by an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes (Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS]),.</p><p>&bull;&nbsp;&nbsp;&nbsp; symptoms such as low urine volume, tiredness, nausea, vomiting, confusion and swelling in the legs, ankles or feet, as this may be a sign of sudden decrease of kidney function</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; a skin rash which may form blisters and look like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a more severe form of rash causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis)</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; signs of serious mental changes or if someone around you notices signs of confusion, somnolence (sleepiness), amnesia (loss of memory), memory impairment (forgetfulness), abnormal behaviour or other neurological signs including involuntary or uncontrolled movements. These could be symptoms of an encephalopathy.</p><p>The most frequently reported adverse reactions were nasopharyngitis, somnolence (sleepiness), headache, fatigue and dizziness. At the beginning of the treatment or at dose increase side effects like sleepiness, tiredness and dizziness may be more common. These effects should however decrease over time.</p><p><strong>Very common</strong>: may affect more than 1 in 10 people</p><p>&bull;&nbsp; nasopharyngitis;</p><p>&bull;&nbsp; somnolence (sleepiness), headache.</p><p><strong>Common</strong>: may affect up to 1 in 10 people</p><p>&bull;&nbsp;&nbsp;&nbsp; anorexia (loss of appetite);</p><p>&bull;&nbsp;&nbsp;&nbsp; depression, hostility or aggression, anxiety, insomnia, nervousness or irritability;</p><p>&bull;&nbsp; convulsion, balance disorder (equilibrium disorder), dizziness (sensation of unsteadiness), lethargy (lack of energy and enthusiasm), tremor (involuntary trembling);</p><p>&bull;&nbsp; vertigo (sensation of rotation);</p><p>&bull;&nbsp; cough;</p><p>&bull;&nbsp; abdominal pain, diarrhoea, dyspepsia (indigestion), vomiting, nausea;</p><p>&bull;&nbsp; rash;</p><p>&bull;&nbsp; asthenia/fatigue (tiredness).</p><p><strong>Uncommon</strong>: may affect up to 1 in 100 people</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased number of blood platelets, decreased number of white blood cells;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight decrease, weight increase;</p><p>&bull;&nbsp;&nbsp;&nbsp; suicide attempt and suicidal ideation, mental disorder, abnormal behaviour, hallucination, anger, confusion, panic attack, emotional instability/mood swings, agitation;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; amnesia (loss of memory), memory impairment (forgetfulness), abnormal coordination/ataxia (impaired coordinated movements), paraesthesia (tingling), disturbance in attention (loss of concentration);</p><p>&bull;&nbsp;&nbsp;&nbsp; diplopia (double vision), vision blurred;</p><p>&bull;&nbsp;&nbsp;&nbsp; elevated/abnormal values in a liver function test;</p><p>&bull;&nbsp;&nbsp;&nbsp; hair loss, eczema, pruritus;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; muscle weakness, myalgia (muscle pain);</p><p>&bull;&nbsp;&nbsp;&nbsp; injury.</p><p><strong>Rare</strong>: may affect up to 1 in 1,000 people</p><p>&bull;&nbsp;&nbsp;&nbsp; infection;</p><p>&bull;&nbsp;&nbsp;&nbsp; decreased number of all blood cell types;</p><p>&bull;&nbsp;&nbsp;&nbsp; severe allergic reactions (DRESS, anaphylactic reaction [severe and important allergic reaction], Quincke&rsquo;s oedema [swelling of the face, lips, tongue and throat]);</p><p>&bull;&nbsp;&nbsp;&nbsp; decreased blood sodium concentration;</p><p>&bull;&nbsp; suicide, personality disorders (behavioural problems), thinking abnormal (slow thinking, unable to concentrate);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; delirium;</p><p>&bull;&nbsp;&nbsp;&nbsp; encephalopathy (see sub-section &ldquo;Tell your doctor immediately&rdquo; for a detailed description of symptoms);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizures may become worse or happen more often;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; uncontrollable muscle spasms affecting the head, torso and limbs, difficulty in controlling movements, hyperkinesia (hyperactivity);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change of the heart rhythm (Electrocardiogram);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pancreatitis;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver failure, hepatitis;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden decrease in kidney function;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme), a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome), and a more severe form causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis);</p><p>&bull;&nbsp;&nbsp;&nbsp; rhabdomyolysis (breakdown of muscle tissue) and associated blood creatine phosphokinase increase. Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; limp or difficulty walking.</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp; Store below 30&deg;C.</p><p>&bull;&nbsp;&nbsp;&nbsp; Keep out of reach of children.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of the month.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Racitam contains</p><p>The active substance is Levetiracetam (Form-I).</p><p>Each milliliter (1 ml) of oral solution contains 100 mg of Levetiracetam Ph.Eur.</p><p>The other ingredients are: Maltitol Liquid, Glycerol, Methyl Parahydroxy benzoate, Propyl Parahydroxy benzoate, Citric acid monohydrate, Sodium citrate, Glycyrrhizinate Ammonium, Acesulfame Potassium, ART Grape FL #10273, Purified Water.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                A clear, colourless grape flavoured liquid filled in 200ml amber coloured glass bottles with EPE wad.
How supplied:
Racitam is Supplied in Amber Colored Glass Bottle.
The 200 ml glass bottle, containing 150 ml of Racitam (for infants and young children aged 6 months to less than 4 years), is packed in a cardboard box containing a 3 ml oral syringe (graduated from 1 ml to 3 ml) and an adaptor for the syringe.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Saudi Amarox Industrial Company</strong></p><p>Al Jamiah Street, Al Malaz District</p><p>Riyadh 12629, Saudi Arabia</p><p>Tel &amp; Fax: +966 11 226 8850&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in January 2024, Version 1.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ليفيتيراسيتام هو دواء مضاد للصرع (دواء يستخدم لعلاج نوبات الصرع).</p><p dir="RTL">يستخدم راسيتام محلول فموي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كعلاج أحادي عند البالغين والمراهقين من سن 16 عامًا ممن تم تشخيصهم حديثًا بالصرع ، لعلاج شكل معين من الصرع. الصرع حالة يصاب فيها المريض بنوبات متكررة (نوبات). يستخدم ليفيتيراسيتام في علاج شكل من أشكال الصرع حيث تؤثر النوبات في البداية على جانب واحد فقط من الدماغ ، ولكن يمكن أن تمتد بعد ذلك إلى مناطق أكبر على جانبي الدماغ (تبدء بالنوبة الجزئية مع أو بدون تعميم ثانوي). يتم وصف ليفيتيراسيتام لك من قبل طبيبك لتقليل عدد النوبات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالإضافة إلى أدوية أخرى مضادة للصرع لعلاج:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بداية النوبات الجزئية مع أو بدون تعميم عند البالغين والمراهقين والأطفال والرضع من شهر واحد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات رمع العضلية (نوبات قصيرة تشبه الصدمة لعضلة أو مجموعة من العضلات) عند البالغين و المراهقون من سن 12 عامًا المصابين بالصرع الرمعي العضلي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات التوترية الارتجاجية المعممة الأولية (النوبات الشاملة ، بما في ذلك فقدان الوعي) عند البالغين والمراهقين من سن 12 عامًا المصابين بالصرع المعمم مجهول السبب (نوع الصرع الذي يُعتقد أن له سبب وراثي).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم راسيتام محلول فموي</strong></p><p dir="RTL">إذا كنت تعاني من حساسية تجاه ليفيتيراسيتام أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL"><strong>التحزيرات والإحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل تناول راسيتام محلول فموي في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في الكلى ، فاتبع تعليمات طبيبك. قد يقرر / تقرر ما إذا كان ينبغي تعديل جرعتك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لاحظت أي تباطؤ في النمو أو تطور البلوغ غير المتوقع لطفلك ، فاتصل بطبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يحدث لدى عدد قليل من الأشخاص الذين يعالجون بمضادات الصرع مثل راسيتام محلول فموي أفكار لإيذاء أنفسهم أو الانتحار. إذا كان لديك أي أعراض للاكتئاب و / أو التفكير في الانتحار ، يرجى الاتصال بطبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ عائلي أو طبي من عدم انتظام ضربات القلب (يظهر في مخطط كهربية القلب) ، أو إذا كنت مصابًا بمرض و / أو تتناول علاجًا يجعلك عرضة لاضطراب ضربات القلب أو عدم توازن الأملاح بالجسم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك أو الصيدلي إذا تفاقمت أي من الآثار الجانبية التالية أو استمرت أكثر من بضعة أيام:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأفكار غير الطبيعية ، والشعور بالضيق أو الاستجابة بشكل أكثر عدوانية من المعتاد ، أو إذا لاحظت أنت أولاحظ أفراد عائلتك وأصدقاؤك تغيرات مهمة في الحالة المزاجية أو السلوك الخاصة بك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>تفاقم الصرع</u></p><p dir="RTL">نادرا ما تتفاقم نوباتك أو تحدث في كثير من الأحيان ، خاصة خلال الشهر الأول بعد بدء العلاج أو زيادة الجرعة. إذا واجهت أيًا من هذه الأعراض الجديدة أثناء تناول راسيتام محلول فموي استشر الطبيب في أقرب وقت ممكن.</p><p dir="RTL"><strong>الأطفال و المراهقين</strong></p><p dir="RTL">لا يتم وصف راسيتام محلول فموي للأطفال والمراهقين (الذين تبلغ أعمارهم 16 عامًا) كعلاج أحادي.</p><p dir="RTL"><strong>الأدوية الأخرى و</strong><strong> </strong><strong>راسيتام محلول فموي</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL"><strong>لا تتناول ماكروجول (دواء يستخدم كملين) لمدة ساعة واحدة قبل تناول ليفيتيراسيتام وساعة واحدة بعده لأن هذا قد يؤدي إلى تقليل تأثيره.</strong></p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنت حاملاً أو مرضعة ، أو تعتقدين أنك حامل ، أو تخططين لإنجاب طفل ، فاسألي طبيبك للحصول على المشورة قبل تناول هذا الدواء. يمكن استخدام ليفيتيراسيتام أثناء الحمل ، فقط إذا اعتبره طبيبك ضروريًا بعد التقييم الدقيق.</p><p dir="RTL">يجب ألا تتوقف عن العلاج دون مناقشة هذا الأمر مع طبيبك.</p><p dir="RTL">لا يمكن تمامًا استبعاد خطر حدوث عيوب خلقية لجنينك.</p><p dir="RTL">لا ينصح بالرضاعة الطبيعية أثناء العلاج باستخدام راسيتام محلول فموي.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يضعف راسيتام محلول فموي قدرتك على القيادة أو تشغيل أي أدوات أو آلات ، لأنه قد يجعلك تشعر بالنعاس. تزداد احتمالية حدوث ذلك في بداية العلاج أو بعد زيادة الجرعة. يجب عدم القيادة أو استخدام الآلات حتى يتم التأكد من عدم تأثر قدرتك على أداء مثل هذه الأنشطة.</p><p dir="RTL"><strong>يحتوي راسيتام محلول فموي على ميثيل باراهيدروكسي بنزوات وبروبيل باراهيدروكسي بنزوات ومالتيتول</strong></p><p dir="RTL">يحتوي محلول راسيتام الفموي على ميثيل باراهيدروكسي بنزوات (E218) وبروبيل باراهيدروكسي بنزوات (E216) الذي قد يسبب تفاعلات حساسية (ربما تتأخر).</p><p dir="RTL"><strong>يحتوي محلول راسيتام الفموي أيضًا على مالتيتول. إذا أخبرك طبيبك أن لديك حساسية تجاه بعض السكريات ، فاتصل بطبيبك قبل تناول هذا المنتج الطبي.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL">يجب تناول راسيتام محلول فموي مرتين في اليوم ، مرة في الصباح ومرة في المساء ، في نفس الوقت تقريبًا كل يوم.</p><p dir="RTL">يجب اتباع تعليمات الطبيب في كيفية تناول المحلول الفموي .</p><p dir="RTL"><strong>العلاج الأحادي (من سن 16 عامًا)</strong></p><p dir="RTL"><strong>البالغون (أكبر من 18 عامًا) والمراهقون (من سن 16 عامًا):</strong></p><p dir="RTL">قم بقياس الجرعة المناسبة باستخدام المحقنة الموجودة في العبوة لمرضى 4 سنوات وما فوق.</p><p dir="RTL">الجرعة العامة: يتم تناول راسيتام محلول فموي مرتين يوميًا ، على جرعتين متساويتين ، يتم قياس كل جرعة فردية بين 5 مل (500 ملجرام) و 15 مل (1500 ملجرام).</p><p dir="RTL">عندما تبدأ بتناول راسيتام محلول فموي لأول مرة ، سيصف لك طبيبك جرعة أقل خلال أسبوعين قبل إعطائك أقل جرعة عامة.</p><p dir="RTL"><strong>العلاج الإضافي</strong></p><p dir="RTL"><strong>جرعة البالغين والمراهقين (12 إلى 17 سنة):</strong></p><p dir="RTL">قم بقياس الجرعة المناسبة باستخدام المحقنة الموجودة في العبوة لمرضى 4 سنوات وما فوق.</p><p dir="RTL">الجرعة العامة: يتم تناول راسيتام محلول فموي مرتين يوميًا ، على جرعتين متساويتين ، يتم قياس كل جرعة فردية بين 5 مل (500 ملجرام) و 15 مل (1500 ملجرام).</p><p dir="RTL"><strong>الجرعة للأطفال بعمر 6 أشهر فما فوق:</strong></p><p dir="RTL">سيصف لك طبيبك الشكل الصيدلاني الأنسب لـ راسيتام محلول فموي وفقًا للعمر والوزن والجرعة.</p><p dir="RTL">للأطفال من سن 6 أشهر إلى 4 سنوات ، قم بقياس الجرعة المناسبة باستخدام محقنة 3 مل الموجودة في العبوة.</p><p dir="RTL">قم بقياس الجرعة المناسبة باستخدام المحقنة الموجودة في العبوة لمرضى 4 سنوات وما فوق.</p><p dir="RTL">الجرعة العامة: يتم تناول راسيتام محلول فموي مرتين يوميًا ، على جرعتين متساويتين ، يتم قياس كل جرعة فردية بين 0.1 مل (10 ملجرام) و 0.3 مل (30 ملجرام) ، لكل كغم من وزن جسم الطفل. (انظر الجدول أدناه للحصول على أمثلة الجرعات).</p><p dir="RTL"><strong>الجرعة للأطفال بعمر 6 أشهر فما فوق:</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:346px"><tbody><tr><td><p dir="RTL"><strong>الوزن</strong></p></td><td><p dir="RTL"><strong>جرعة البدء:</strong></p><p dir="RTL"><strong>0.1 مل / كجم مرتين يومياً</strong></p></td><td><p dir="RTL"><strong>الجرعة القصوى:</strong></p><p dir="RTL"><strong>0.3 مل / كجم مرتين يومياً</strong></p></td></tr><tr><td><p dir="RTL">6 كغم</p></td><td><p dir="RTL">0.6 مل مرتين يومياً</p></td><td><p dir="RTL">1.8 مل مرتين يومياً</p></td></tr><tr><td><p dir="RTL">8 كغم</p></td><td><p dir="RTL">0.8 مل مرتين يومياً</p></td><td><p dir="RTL">2.4 مل مرتين يومياً</p></td></tr><tr><td><p dir="RTL">10 كغم</p></td><td><p dir="RTL">1 مل مرتين يومياً</p></td><td><p dir="RTL">3 مل مرتين يومياً</p></td></tr><tr><td><p dir="RTL">15 كغم</p></td><td><p dir="RTL">1.5 مل مرتين يومياً</p></td><td><p dir="RTL">4.5 مل مرتين يومياً</p></td></tr><tr><td><p dir="RTL">20 كغم</p></td><td><p dir="RTL">2 مل مرتين يومياً</p></td><td><p dir="RTL">6 مل مرتين يومياً</p></td></tr><tr><td><p dir="RTL">25 كغم</p></td><td><p dir="RTL">2.5 مل مرتين يومياً</p></td><td><p dir="RTL">7.5 مل مرتين يومياً</p></td></tr><tr><td><p dir="RTL">من 50 كغم</p></td><td><p dir="RTL">5 مل مرتين يومياً</p></td><td><p dir="RTL">15 مل مرتين يومياً</p></td></tr></tbody></table><p dir="RTL">جرعة الرضع (من شهر إلى أقل من 6 أشهر):</p><p dir="RTL"><strong>بالنسبة للرضع من شهر إلى أقل من 6 أشهر</strong> ، يجب قياس الجرعة المناسبة باستخدام المحقنة الموجودة في العبوة.</p><p dir="RTL">الجرعة العامة: يتم تناول راسيتام محلول فموي مرتين يوميًا ، على جرعتين متساويتين ، يتم قياس كل جرعة فردية بين 0.07 مل (7 ملجرام) و 0.21 مل (21 ملجرام) ، لكل كغم من وزن الرضيع. (انظر الجدول أدناه للحصول على أمثلة الجرعات).</p><p dir="RTL">جرعة الرضع (من شهر إلى أقل من 6 أشهر):</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:360px"><tbody><tr><td><p dir="RTL"><strong>الوزن</strong></p></td><td><p dir="RTL"><strong>جرعة البدء:</strong></p><p dir="RTL"><strong>0.07 مل / كجم مرتين يومياً</strong></p></td><td><p dir="RTL"><strong>الجرعة القصوى:</strong></p><p dir="RTL"><strong>0.21 مل / كجم مرتين يومياً</strong></p></td></tr><tr><td><p dir="RTL">4 كغم</p></td><td><p dir="RTL">0.3 مل مرتين يومياً</p></td><td><p dir="RTL">0.85 مل مرتين يومياً</p></td></tr><tr><td><p dir="RTL">5 كغم</p></td><td><p dir="RTL">0.35 مل مرتين يومياً</p></td><td><p dir="RTL">1.05 مل مرتين يومياً</p></td></tr><tr><td><p dir="RTL">6 كغم</p></td><td><p dir="RTL">0.45 مل مرتين يومياً</p></td><td><p dir="RTL">1.25 مل مرتين يومياً</p></td></tr><tr><td><p dir="RTL">7 كغم</p></td><td><p dir="RTL">0.5 مل مرتين يومياً</p></td><td><p dir="RTL">1.5 مل مرتين يومياً</p></td></tr></tbody></table><p dir="RTL"><strong>طريقة التناول:</strong></p><p dir="RTL">بعد قياس الجرعة الصحيحة بحقنة مناسبة ، يمكن تخفيف محلول راسيتام الفموي في كوب من الماء أو زجاجة الطفل. يمكنك تناول راسيتام محلول فموي مع أو بدون طعام. بعد تناوله عن طريق الفم ، قد يحدث الشعور بالطعم المر من ليفيتيراسيتام.</p><p dir="RTL"><strong>تعليمات الاستخدام:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; افتح الزجاجة: اضغط على الغطاء وأدره عكس اتجاه عقارب الساعة (الشكل 1)</p><p dir="RTL"><br /><img src="data:image/png;base64,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" alt="" vspace="0" hspace="0" border="0" style="margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p dir="RTL">افصل المحول عن المحقنة (الشكل 2). أدخل المحول في عنق الزجاجة (الشكل 3) وتأكد من تثبيته جيدًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خذ المحقنة وضعها في فتحة المحول (شكل 4). اقلب الزجاجة رأسًا على عقب (الشكل 5).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; املأ المحقنة بكمية صغيرة من المحلول عن طريق سحب المكبس لأسفل (الشكل 5 A) ، ثم ادفع المكبس لأعلى لإزالة أي فقاعة محتملة (الشكل 5 B). اسحب المكبس لأسفل حتى علامة التخرج المقابلة للكمية بالملليترات (مل) التي وصفها طبيبك (الشكل 5 C).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اقلب الزجاجة في الاتجاه الصحيح (الشكل 6 A). قم بإزالة المحقنة من المحول (الشكل 6 B).</p><p dir="RTL">&nbsp;</p><p dir="RTL">أفرغ محتويات المحقنة في كوب من الماء أو زجاجة الطفل عن طريق دفع المكبس إلى أسفل المحقنة (الشكل 7).</p><p dir="RTL">&nbsp;</p><p dir="RTL">اشرب كامل محتويات الزجاجة / زجاجة الطفل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أغلق الزجاجة بالغطاء اللولبي البلاستيكي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اغسل المحقنة بالماء فقط (شكل 8).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مدة العلاج:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يستخدم راسيتام محلول فموي كعلاج مزمن. يجب أن تستمر في تناول علاج راسيتام محلول فموي طوال الوقت الذي أخبرك به طبيبك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتوقف عن علاجك بدون نصيحة طبيبك لأن هذا قد يزيد من نوباتك.</p><p dir="RTL"><strong>إذا تناولت </strong><strong>جرعة زائدة من </strong><strong>راسيتام محلول فموي</strong><strong> </strong></p><p dir="RTL">الآثار الجانبية المحتملة لجرعة زائدة من راسيتام محلول فموي هي النعاس والإثارة والعدوانية ونقص اليقظة وتثبيط التنفس والغيبوبة.</p><p dir="RTL">اتصل بطبيبك إذا تناولت راسيتام محلول فموي أكثر مما ينبغي. سيحدد طبيبك أفضل علاج ممكن للجرعة الزائدة.</p><p dir="RTL"><strong>إذا نسيت أن تتناول </strong><strong>راسيتام محلول فموي</strong><strong>:</strong></p><p dir="RTL">اتصل بطبيبك إذا فاتتك جرعة واحدة أو أكثر.</p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL"><strong>التوقف عن تناول راسيتام محلول فموي:</strong></p><p dir="RTL">في حالة التوقف عن العلاج ، يجب إيقاف راسيتام محلول فموي تدريجيًا لتجنب زيادة النوبات. إذا قرر طبيبك إيقاف علاج راسيتام محلول فموي الخاص بك ، فسوف يرشدك بشأن الانسحاب التدريجي لنظام راسيتام محلول فموي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية ، يمكن أن يسبب هذا الدواء آثارًا جانبية ، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL"><strong>أخبر طبيبك على الفور ، أو اذهب إلى أقرب قسم طوارئ ، إذا واجهت:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الضعف ، الشعور بالدوخة أو الدوار أو صعوبة التنفس ، حيث قد تكون هذه علامات لرد فعل تحسسي خطير (الحساسية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الوجه والشفتين واللسان والحلق (وذمة وعائية أو وذمة كوينك)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض شبيهة بالإنفلونزا وطفح جلدي على الوجه يتبعها طفح جلدي ممتد مع ارتفاع في درجة الحرارة ، وزيادة مستويات إنزيمات الكبد التي تظهر في اختبارات الدم وزيادة في نوع من خلايا الدم البيضاء (فرط الحمضات) وتضخم الغدد الليمفاوية (التفاعل الدوائي المترافق مع فرط الحمضات والأعراض الجهازية [DRESS]).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض مثل انخفاض كمية البول ، والتعب ، والغثيان ، والقيء ، والارتباك ، والتورم في الساقين أو الكاحلين أو القدمين ، لأن هذا قد يكون علامة على قصور مفاجئ في وظائف الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي قد يشكل بثور وتبدو وكأنها صغيرة (بقع داكنة مركزية محاطة بمنطقة باهته ، مع حلقة داكنة حول الحافة) (حمامي عديدة الأشكال)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي واسع الانتشار مصحوبًا ببثور وتقشر الجلد ، خاصة حول الفم والأنف والعينين والأعضاء التناسلية (متلازمة ستيفنز جونسون)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي بشكل أكثر حدة اللذي يسبب تقشير الجلد في أكثر من 30٪ من سطح الجسم (انحلال الجلد السمي النخري)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات التغيرات العقلية الخطيرة أو إذا لاحظ شخص من حولك علامات الارتباك ، والنعاس ، وفقدان الذاكرة ، وضعف الذاكرة (النسيان) ، والسلوك غير الطبيعي أو علامات عصبية أخرى بما في ذلك الحركات اللاإرادية أو الغير منضبطة. يمكن أن تكون هذه أعراض اعتلال دماغي.</p><p dir="RTL">من الآثار الجانبية الأكثر شيوعًا هي التهاب البلعوم الأنفي ، والنعاس ، والصداع ، والإرهاق ، والدوخة. في بداية العلاج أو عند زيادة الجرعة ، قد تكون الآثار الجانبية مثل النعاس والتعب والدوخة أكثر شيوعًا. ومع ذلك ، يجب أن تنخفض هذه التأثيرات بمرور الوقت.</p><p dir="RTL">شائعة جدًا: قد تظهر لدى أكثر من 1 من كل 10 أشخاص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البلعوم الأنفي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النعاس والصداع.</p><p dir="RTL">شائعة: قد تظهر لدى حتى 1 من كل 10 أشخاص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاكتئاب ، العداء أو العدوانية ، القلق ، الأرق ، العصبية أو التهيج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنج ، اضطراب التوازن ، الدوخة (الإحساس بعدم الثبات) ، الخمول (نقص الطاقة والحماس) ، الرعاش (الارتعاش اللاإرادي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار (الإحساس بالدوران).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في البطن ، إسهال ، عسر الهضم ، قيء ، غثيان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوهن / التعب.</p><p dir="RTL">غير شائعة: قد تظهر لدى حتى 1 من كل 100 شخص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الصفائح الدموية ، انخفاض عدد خلايا الدم البيضاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الوزن ، زيادة الوزن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; محاولة الانتحار والتفكير في الانتحار ، والاضطراب العقلي ، والسلوك غير الطبيعي ، والهلوسة ، والغضب ، والارتباك ، ونوبات الهلع ، وعدم الاستقرار العاطفي / تقلب المزاج ، والانفعالات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الذاكرة ، ضعف الذاكرة (النسيان) ، اختلال الحركة / ترنح (ضعف الحركات المنسقة) ، تنمل (وخز) ، اضطراب في الانتباه (فقدان التركيز) ؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرؤية المزدوجة ، عدم وضوح الرؤية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيم مرتفعة / غير طبيعية في اختبار وظائف الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر ، والأكزيما ، والحكة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات ، ألم عضلي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إصابة.</p><p dir="RTL">نادرة: قد تظهر لدى حتى 1 من كل 1000 شخص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد جميع أنواع خلايا الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية شديدة (التفاعل الدوائي المترافق مع فرط الحمضات والأعراض الجهازية [DRESS]) ، وذمة كوينك (الوذمة الوعائية) [تورم الوجه والشفتين واللسان والحلق]) ؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الصوديوم في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانتحار ، اضطرابات الشخصية (المشاكل السلوكية) ، التفكير غير الطبيعي (التفكير البطيء ، عدم القدرة على التركيز).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هذيان؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اعتلال الدماغ (انظر القسم الفرعي &quot;أخبر طبيبك على الفور&quot; للحصول على وصف مفصل للأعراض) ؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تتفاقم النوبات أو تحدث في كثير من الأحيان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات عضلية لا يمكن السيطرة عليها تؤثر على الرأس والجذع والأطراف ، وصعوبة في السيطرة على الحركات ، وفرط الحركة (فرط النشاط).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيير ضربات القلب (مخطط كهربية القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل الكبد والتهاب الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مفاجئ في وظائف الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي ، الذي قد يشكل بثور ويبدو وكأنه صغيرة (بقع داكنة مركزية محاطة بمنطقة باهتة ، مع حلقة داكنة حول الحافة) (حمامي عديدة الأشكال) ، طفح جلدي منتشر مع ظهور بثور وتقشير الجلد ، خاصة حول الفم والأنف والعينين والأعضاء التناسلية (متلازمة ستيفنز جونسون) ، والشكل الأكثر خطورة يسبب تقشر الجلد في أكثر من 30٪ من سطح الجسم (انحلال البشرة السمي النخري) ؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انحلال الربيدات (انهيار الأنسجة العضلية) وزيادة إنزيم فوسفوكيناز الكرياتين المرتبط بالدم. معدل شيوع هذا التأثير الجانبي أعلى بشكل ملحوظ في المرضى اليابانيين مقارنة بالمرضى غير اليابانيين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العرج أو صعوبة في المشي.</p><p><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p>إن كان لديك أعراض جانبية أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، فضلًا ابلغ الطبيب أو مقدم الرعاية الصحية أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ هذا الدواء بعيدًا عن رؤية ومتناول أيدي الأطفال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة بعد EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا تحتوي راسيتام محلول فموي على:</strong></p><p dir="RTL">المادة الفعالة هي ليفيتيراسيتام (Form-I).</p><p dir="RTL">يحتوي كل مليلتر (1 مل) من المحلول الفموي على 100 ملجرام من ليفيتيراسيتام المتوافق مع دستور الأدوية الأوروبي.</p><p dir="RTL">الصواغات الأخرى هي: مالتيتول السائل ، جلسرين ، ميثيل باراهيدروكسي بنزوات ، بروبيل باراهيدروكسي بنزوات ، حمض الستريك الأحادي الهيدرات ، سترات الصوديوم ، جليسيرريزينات الأمونيوم ، أسيسولفام البوتاسيوم ، نكهة العنب ART ذات كود FL # 10273 ، ماء نقي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل راسيتام محلول فموي ؟</strong></p><p dir="RTL">عبوة زجاجية ملونة باللون الداكن سعة 200 مل مملوءة بسائل شفاف عديم اللون بنكهة العنب مع سداداه من EPE</p><p dir="RTL"><strong>كيفية توفير راسيتام محلول فموي ؟</strong></p><p dir="RTL">يتم توفير راسيتام محلول فموي في عبوة زجاجية ملونة باللون الداكن.</p><p dir="RTL">عبوة زجاجية سعة 200 مل ، تحتوي على 150 مل من راسيتام محلول فموي (للرضع والأطفال الصغار الذين تتراوح أعمارهم بين 6 أشهر إلى أقل من 4 سنوات) ، معبأة في علبة من الورق المقوى يحتوي على حقنة 3 مل للإستخدام عن طريق الفم (متدرجة من 1 مل إلى 3 مل) و محول للحقنة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب حق التسويق</strong><strong>:</strong></p><p><strong>شركة أماروكس السعودية للصناعة</strong></p><p>شارع الجامعة ، حي الملز</p><p>الرياض 12629 ، المملكة العربية السعودية</p><p>هاتف و فاكس: 966112268850+</p><p dir="RTL"><strong>المصنع</strong><strong>: </strong></p><p>هتيرو لاب المحدودة - الوحدة الثالثة - الهند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في يناير 2024 ، نسخة 1
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Racitam (Levetiracetam Oral Solution 100mg/mL)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Racitam (Levetiracetam Oral Solution 100mg/mL)
Each milliliter (1 ml) of oral solution contains 100 mg of Levetiracetam Ph.Eur.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Racitam (Levetiracetam Oral Solution 100mg/mL)
A clear, colourless grape flavoured liquid filled in 200ml amber coloured glass bottles with EPE wad.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>1.1&nbsp; </strong><strong>Therapeutic indications</strong></p><p>Racitam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.</p><p>Racitam is indicated as adjunctive therapy</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp; Posology</p><p>Partial onset seizures</p><p>The recommended dosing for monotherapy (from 16 years of age) and adjunctive therapy is the same; as outlined below.</p><p>All indications</p><p>Adults (&ge;18 years) and adolescents (12 to 17 years) weighing 50 kg or more</p><p>&nbsp;</p><p>The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment. However, a lower initial dose of 250 mg twice daily may be given based on physician assessment of seizure reduction versus potential side effects. This can be increased to 500 mg twice daily after two weeks.</p><p>Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 250 mg or 500 mg twice daily increases or decreases every two to four weeks.</p><p>Adolescents (12 to 17 years) weighing below 50 kg and children from 1 month of age</p><p>The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to weight, age and dose. Refer to Paediatric population section for dosing adjustments based on weight.</p><p>Discontinuation</p><p>If levetiracetam has to be discontinued it is recommended to withdraw it gradually (<em>e.g</em>. in adults and adolescents weighing more than 50 kg: 500 mg decreases twice daily every two to four weeks; in infants older than 6 months, children and adolescents weighing less than 50 kg: dose decrease should not exceed 10 mg/kg twice daily every two weeks; in infants (less than 6 months): dose decrease should not exceed 7 mg/ kg twice daily every two weeks).</p><p>Special populations</p><p>Elderly (65 years and older)</p><p>Adjustment of the dose is recommended in elderly patients with compromised renal function (see &ldquo;Renal impairment&rdquo; below).</p><p>Renal impairment</p><p>The daily dose must be individualised according to renal function.</p><p>For adult patients, refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient&#39;s creatinine clearance (CLcr) in ml/min is needed. The CLcr in ml/min may be estimated from serum creatinine (mg/dl) determination, for adults and adolescents weighing 50 kg or more, the following formula:</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Image_x0020_18" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:324.75pt;height:124.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title=""/>
 <o:lock v:ext="edit" aspectratio="f"/>
</v:shape><![endif]--><img width="433" height="166" alt="" vspace="0" hspace="0" border="0" style="width:433px;height:166px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></p><p>Dosing adjustment for adult and adolescent patients weighing more than 50 kg with impaired renal function:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Group</p></td><td style="vertical-align:top"><p>Creatinine clearance (ml/min/1.73m<sup>2</sup>)</p></td><td style="vertical-align:top"><p>Dose and frequency</p></td></tr><tr><td style="vertical-align:top"><p>Normal Mild Moderate Severe</p><p>End-stage renal disease patients undergoing dialysis (1)</p></td><td style="vertical-align:top"><p>&gt; 80</p><p>50-79</p><p>30-49</p><p>&lt; 30</p><p>-</p></td><td style="vertical-align:top"><p>500 to 1,500 mg twice daily</p><p>500 to 1,000 mg twice daily</p><p>250 to 750 mg twice daily</p><p>250 to 500 mg twice daily</p><p>500 to 1,000 mg once daily (2)</p></td></tr></tbody></table><p>(1)&nbsp; A 750 mg loading dose is recommended on the first day of treatment with levetiracetam.</p><p>(2)&nbsp; Following dialysis, a 250 to 500 mg supplemental dose is recommended.</p><p>For children with renal impairment, levetiracetam dose needs to be adjusted based on the renal function as levetiracetam clearance is related to renal function. This recommendation is based on a study in adult renally impaired patients.</p><p>The CLcr in ml/min/1.73 m2 may be estimated from serum creatinine (mg/dl) determination, for young adolescents, children and infants, using the following formula (Schwartz formula):</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="Image_x0020_19" o:spid="_x0000_s2050" type="#_x0000_t75" style='position:absolute;
  margin-left:96.1pt;margin-top:6.9pt;width:313.9pt;height:48.25pt;z-index:-15727616;
  visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg"
   o:title=""/>
  <o:lock v:ext="edit" aspectratio="f"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="419" height="64" alt="" vspace="0" hspace="0" border="0" style="width:419px;height:64px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>ks= 0.45 in Term infants to 1 year old; ks= 0.55 in Children to less than 13 years and in adolescent female; ks= 0.7 in adolescent male</p><p>&nbsp;</p><p>Dosing adjustment for infants, children and adolescent patients weighing less than 50 kg with impaired renal function:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Group</p></td><td rowspan="2" style="vertical-align:top"><p>Creatinine&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; clearance (ml/min/1.73 m<sup>2</sup>)</p></td><td colspan="2" style="vertical-align:top"><p>Dose and frequency (1)</p></td></tr><tr><td style="vertical-align:top"><p>Infants 1 to less than 6 months</p></td><td style="vertical-align:top"><p>Infants 6 to 23 months, children and adolescents weighing less than 50 kg</p></td></tr><tr><td style="vertical-align:top"><p>Normal</p></td><td style="vertical-align:top"><p>&gt; 80</p></td><td style="vertical-align:top"><p>7 to 21 mg/kg (0.07 to 0.21 ml/kg) twice daily</p></td><td style="vertical-align:top"><p>10 to 30 mg/kg (0.10 to 0.30 ml/kg) twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Mild</p></td><td style="vertical-align:top"><p>50-79</p></td><td style="vertical-align:top"><p>7 to 14 mg/kg (0.07 to 0.14 ml/kg) twice daily</p></td><td style="vertical-align:top"><p>10 to 20 mg/kg (0.10 to 0.20 ml/kg) twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Moderate</p></td><td style="vertical-align:top"><p>30-49</p></td><td style="vertical-align:top"><p>3.5 to 10.5 mg/kg (0.035 to 0.105 ml/kg) twice daily</p></td><td style="vertical-align:top"><p>5 to 15 mg/kg (0.05 to 0.15 ml/kg) twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Severe</p></td><td style="vertical-align:top"><p>&lt; 30</p></td><td style="vertical-align:top"><p>3.5 to 7 mg/kg (0.035 to 0.07 ml/kg) twice daily</p></td><td style="vertical-align:top"><p>5 to 10 mg/kg (0.05 to 0.10 ml/kg) twice daily</p></td></tr><tr><td style="vertical-align:top"><p>End-stage renal disease patients undergoing dialysis</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>7 to 14 mg/kg (0.07 to 0.14 ml/kg) once daily</p><p>(2) (4)</p></td><td style="vertical-align:top"><p>10 to 20 mg/kg (0.10 to 0.20 ml/kg) once daily</p><p>(3) (5)</p></td></tr></tbody></table><p>(1)&nbsp;&nbsp; Racitam should be used for doses under 250 mg, for doses not multiple of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets.</p><p>(2)&nbsp;&nbsp; A 10.5 mg/kg (0.105 ml/kg) loading dose is recommended on the first day of treatment with levetiracetam.</p><p>(3)&nbsp;&nbsp; A 15 mg/kg (0.15 ml/kg) loading dose is recommended on the first day of treatment with levetiracetam.</p><p>(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Following dialysis, a 3.5 to 7 mg/kg (0.035 to 0.07 ml/kg) supplemental dose is recommended.</p><p>&nbsp;</p><p>(5)&nbsp; Following dialysis, a 5 to 10 mg/kg (0.05 to 0.10 ml/kg) supplemental dose is recommended. Hepatic impairment</p><p>No dose adjustment is needed in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the creatinine clearance may underestimate the renal insufficiency. Therefore a 50 % reduction of the daily</p><p>maintenance dose is recommended when the creatinine clearance is &lt; 60 ml/min/1.73 m2. Paediatric population</p><p>The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to age,</p><p>weight and dose.</p><p>Racitam is the preferred formulation for use in infants and children under the age of 6 years. In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg. In all of the above cases Racitam should be used.</p><p>Monotherapy</p><p>The safety and efficacy of Racitam in children and adolescents below 16 years as monotherapy treatment have not been established.</p><p>No data are available.</p><p>Adolescents (16 and 17 years of age) weighing 50 kg or more with partial onset seizures with or without secondary generalisation with newly diagnosed epilepsy</p><p>Please refer to the above section on Adults (&ge;18 years) and adolescents (12 to 17 years) weighing 50 kg or more.</p><p>Add-on therapy for infants aged 6 to 23 months, children (2 to 11 years) and adolescents (12 to 17 years) weighing less than</p><p>50 kg</p><p>The initial therapeutic dose is 10 mg/kg twice daily.</p><p>Depending upon the clinical response and tolerability, the dose can be increased by 10 mg/kg twice daily every 2 weeks up to 30 mg/kg twice daily. Dose changes should not exceed increases</p><p>&nbsp;</p><p>or decreases of 10 mg/kg twice daily every two weeks. The lowest effective dose should be used for all indications.</p><p>Dose in children 50 kg or greater is the same as in adults for all indications.</p><p>Please refer to the above section on Adults (&ge;18 years) and adolescents (12 to 17 years) weighing 50 kg or more for all indications.</p><p>Dose recommendations for infants from 6 months of age, children and adolescents:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>Starting dose:</p><p>10 mg/kg twice daily</p></td><td style="vertical-align:top"><p>Maximum dose: 30 mg/kg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>6 kg (1)</p></td><td style="vertical-align:top"><p>60 mg (0.6 ml) twice daily</p></td><td style="vertical-align:top"><p>180 mg (1.8 ml) twice daily</p></td></tr><tr><td style="vertical-align:top"><p>10 kg <sup>(1)</sup></p></td><td style="vertical-align:top"><p>100 mg (1 ml) twice daily</p></td><td style="vertical-align:top"><p>300 mg (3 ml) twice daily</p></td></tr><tr><td style="vertical-align:top"><p>15 kg <sup>(1)</sup></p></td><td style="vertical-align:top"><p>150 mg (1.5 ml) twice daily</p></td><td style="vertical-align:top"><p>450 mg (4.5 ml) twice daily</p></td></tr><tr><td style="vertical-align:top"><p>20 kg <sup>(1)</sup></p></td><td style="vertical-align:top"><p>200 mg (2 ml) twice daily</p></td><td style="vertical-align:top"><p>600 mg (6 ml) twice daily</p></td></tr><tr><td style="vertical-align:top"><p>25 kg</p></td><td style="vertical-align:top"><p>250 mg twice daily</p></td><td style="vertical-align:top"><p>750 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>From 50 kg <sup>(2)</sup></p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>1,500 mg twice daily</p></td></tr></tbody></table><p>&nbsp;</p><p>(1)&nbsp;&nbsp; Children 25 kg or less should preferably start the treatment with Levetiracetam 100 mg/ml oral solution.</p><p>(2)&nbsp; Dose in children and adolescents 50 kg or more is the same as in adults. Add-on therapy for infants aged from 1 month to less than 6 months</p><p>The initial therapeutic dose is 7 mg/kg twice daily.</p><p>Depending upon the clinical response and tolerability, the dose can be increased by 7 mg/kg twice daily every 2 weeks up to recommended dose of 21 mg/kg twice daily. Dose changes should not exceed increases or decreases of 7 mg/kg</p><p>twice daily every two weeks. The lowest effective dose should be used. Infants should start the treatment with Racitam 100 mg/ml oral solution. Dose recommendations for infants aged from 1 month to less than 6 months:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>Starting dose:</p></td><td style="vertical-align:top"><p>Maximum dose:</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>7 mg/kg twice daily</p></td><td style="vertical-align:top"><p>21 mg/kg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>4 kg</p></td><td style="vertical-align:top"><p>28 mg (0.3 ml) twice daily</p></td><td style="vertical-align:top"><p>84 mg (0.85 ml) twice daily</p></td></tr><tr><td style="vertical-align:top"><p>5 kg</p></td><td style="vertical-align:top"><p>35 mg (0.35 ml) twice daily</p></td><td style="vertical-align:top"><p>105 mg (1.05 ml) twice daily</p></td></tr><tr><td style="vertical-align:top"><p>7 kg</p></td><td style="vertical-align:top"><p>49 mg (0.5 ml)twice daily</p></td><td style="vertical-align:top"><p>147 mg (1.5 ml) twice daily</p></td></tr></tbody></table><p>The below presentation is available:</p><p>- A 150 ml bottle with a 3 ml oral syringe (delivering up to 300 mg levetiracetam) graduated every 0.1 ml (corresponding to 10 mg)</p><p>In order to ensure the accuracy of the dosing, this presentation should be prescribed for infants and young children aged from 6 months to less than 4 years.</p><p>Method of administration</p><p>The oral solution may be diluted in a glass of water or baby&#39;s bottle and may be taken with or without food. After oral administration the bitter taste of levetiracetam may be experienced</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or other pyrrolidone derivatives or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Renal impairment</u></p><p>The administration of levetiracetam to patients with renal impairment may require dose adjustment. In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection (see section 4.2).</p><p><u>Acute Kidney injury</u></p><p>The use of levetiracetam has been very rarely associated with acute kidney injury, with a time to onset ranging from a few days to several months.</p><p><u>Blood cell counts</u></p><p>Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia) have been described in association with levetiracetam administration, generally at the beginning of the treatment. Complete blood cell counts are</p><p>&nbsp;</p><p>advised in patients experiencing important weakness, pyrexia, recurrent infections or coagulation disorders (section 4.8).</p><p><u>Suicide</u></p><p>Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents (including levetiracetam). A meta-analysis of randomized placebo- controlled trials of anti-epileptic medicinal products has shown a small increased risk of suicidal thoughts and behaviour. The mechanism of this risk is not known.</p><p>Therefore, patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or behaviour emerge.</p><p><u>Abnormal and aggressive behaviours</u></p><p>Levetiracetam may cause psychotic symptoms and behavioural abnormalities including irritability and aggressiveness.</p><p>Patients treated with levetiracetam should be monitored for developing psychiatric signs suggesting important mood and/or personality changes. If such behaviours are noticed, treatment adaptation or gradual discontinuation should be considered. If discontinuation is considered, please refer to section 4.2.</p><p><u>Worsening of seizures</u></p><p>As with other types of antiepileptic drugs, levetiracetam may rarely exacerbate seizure frequency or severity. This paradoxical effect was mostly reported within the first month after levetiracetam initiation or increase of the dose, and was reversible upon drug discontinuation or dose decrease. Patients should be advised to consult their physician immediately in case of aggravation of epilepsy.</p><p><u>Electrocardiogram QT interval prolongation</u></p><p>Rare cases of ECG QT interval prolongation have been observed during the post-marketing surveillance. Levetiracetam should be used with caution in patients with QTc-interval prolongation, in patients concomitantly treated with drugs affecting the QTc-interval, or in patients with relevant pre-existing cardiac disease or electrolyte disturbances.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Available data in children did not suggest impact on growth and puberty. However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.</p><p><u>Excipients</u></p><p>Racitam&nbsp;&nbsp;&nbsp; 100&nbsp;&nbsp;&nbsp; mg/ml&nbsp;&nbsp;&nbsp; oral&nbsp;&nbsp;&nbsp; solution&nbsp;&nbsp;&nbsp; contains&nbsp;&nbsp;&nbsp; methyl&nbsp;&nbsp;&nbsp; parahydroxybenzoate&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp; propyl parahydroxybenzoate which may cause allergic reactions (possibly delayed).</p><p>It also contains maltitol liquid; patients with rare hereditary problems of fructose intolerance should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Antiepileptic medicinal products</u></p><p>Pre-marketing data from clinical studies conducted in adults indicate that levetiracetam did not influence the serum concentrations of existing antiepileptic medicinal products (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these antiepileptic medicinal products did not influence the pharmacokinetics of levetiracetam.</p><p>As in adults, there is no evidence of clinically significant medicinal product interactions in paediatric patients receiving up to 60 mg/kg/day levetiracetam.</p><p>A retrospective assessment of pharmacokinetic interactions in children and adolescents with epilepsy (4 to 17 years) confirmed that adjunctive therapy with orally administered levetiracetam did not influence the steady-state serum concentrations of concomitantly administered carbamazepine and valproate. However, data suggested a 20 % higher levetiracetam clearance in children taking enzyme-inducing antiepileptic medicinal products. Dose adjustment is not required.</p><p><u>Probenecid</u></p><p>Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite, but not of levetiracetam. Nevertheless, the concentration of this metabolite remains low.</p><p><u>Methotrexate</u></p><p>&nbsp;</p><p>Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels. Blood methotrexate and levetiracetam levels should be carefully monitored in patients treated concomitantly with the two drugs.</p><p><u>Oral contraceptives and other pharmacokinetics interactions</u></p><p>Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinyl-estradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified. Levetiracetam 2,000 mg daily did not influence the pharmacokinetics of digoxin and warfarin; prothrombin times were not modified. Coadministration with digoxin, oral contraceptives and warfarin did not influence the pharmacokinetics of levetiracetam.</p><p><u>Laxatives</u></p><p>There have been isolated reports of decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly administered with oral levetiracetam. Therefore, macrogol should not be taken orally for one hour before and for one hour after taking levetiracetam.</p><p><u>Food and alcohol</u></p><p>The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced.</p><p>No data on the interaction of levetiracetam with alcohol are available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of child bearing potential</u></p><p>Specialist advice should be given to women who are of childbearing potential. Treatment with levetiracetam should be reviewed when a woman is planning to become pregnant. As with all antiepileptic medicines, sudden discontinuation of levetiracetam should be avoided as this may lead to breakthrough seizures that could have serious consequences for the woman and the unborn child. Monotherapy should be preferred whenever possible because therapy with multiple antiepileptic medicines AEDs could be associated with a higher risk of congenital malformations than monotherapy, depending on the associated antiepileptics.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>A large amount of postmarketing data on pregnant women exposed to levetiracetam monotherapy (more than 1800, among which in more than 1500 exposure occurred during the 1st trimester) do not suggest an increase in the risk for major congenital malformations. Only limited evidence is available on the neurodevelopment of children exposed to Racitam monotherapy in utero. However, current epidemiological studies (on about 100 children) do not suggest an increased risk of neurodevelopmental disorders or delays.</p><p>Levetiracetam can be used during pregnancy, if after careful assessment it is considered clinically needed. In such case, the lowest effective dose is recommended.</p><p>Physiological changes during pregnancy may affect levetiracetam concentration. Decrease in levetiracetam plasma concentrations has been observed during pregnancy. This decrease is more pronounced during the third trimester (up to 60% of baseline concentration before pregnancy). Appropriate clinical management of pregnant women treated with levetiracetam should be ensured.</p><p><u>Breastfeeding</u></p><p>Levetiracetam is excreted in human breast milk. Therefore, breast-feeding is not recommended. However, if levetiracetam treatment is needed during breastfeeding, the benefit/risk of the treatment should be weighed considering the importance of breastfeeding.</p><p><u>Fertility</u></p><p>No impact on fertility was detected in animal studies (see section 5.3). No clinical data are available, potential risk for human is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levetiracetam has minor or moderate influence on the ability to drive and use machines. Due to possible different individual sensitivity, some patients might experience somnolence or other central nervous system related symptoms, especially at the beginning of treatment or following a dose increase. Therefore, caution is recommended in those patients when performing skilled tasks, <em>e.g</em>. driving vehicles or operating machinery. Patients are advised not to drive or use machines until it is established that their ability to perform such activities is not affected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile</p><p>The most frequently reported adverse reactions were nasopharyngitis, somnolence, headache, fatigue and dizziness.</p><p>The adverse reaction profile presented below is based on the analysis of pooled placebo- controlled clinical trials with all indications studied, with a total of 3,416 patients treated with levetiracetam. These data are supplemented with the use</p><p>of levetiracetam in corresponding open-label extension studies, as well as post-marketing experience. The safety profile of levetiracetam is generally similar across age groups (adult and paediatric patients) and across the approved epilepsy indications.</p><p>Tabulated list of adverse reactions</p><p>Adverse reactions reported in clinical studies (adults, adolescents, children and infants &gt; 1 month) and from postmarketing experience are listed in the following table per System Organ Class and per frequency. Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (&ge;1/10);</p><p>common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000) and very rare (&lt;1/10,000).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>MedDRA SOC</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Frequency category</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and infestations</p></td><td style="vertical-align:top"><p>Nasopharyngitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Infection</p></td></tr><tr><td style="vertical-align:top"><p>Blood&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</p><p>lymphatic&nbsp;&nbsp;&nbsp;&nbsp; system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thrombocytopenia, leukopenia</p></td><td style="vertical-align:top"><p>Pancytopenia, neutropenia, agranulocytosis</p></td></tr><tr><td style="vertical-align:top"><p>Immune&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Drug reaction with eosinophilia and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; systemic symptoms</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(DRESS)</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>Weight decreased , weight increase</p></td><td style="vertical-align:top"><p>Hyponatraemia</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Depression,&nbsp;&nbsp;&nbsp; hostility/ aggression,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety, insomnia, nervousness/irritability</p></td><td style="vertical-align:top"><p>Suicide&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; attempt,</p><p>suicidal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ideation psychotic disorder, abnormal behaviour, hallucination, anger,&nbsp;&nbsp;&nbsp; confusional state ,panic attack affect lability/mood swings, agitation</p></td><td style="vertical-align:top"><p>Completed suicide, personality disorder, thinking abnormal, delirium</p></td></tr><tr><td style="vertical-align:top"><p>Nervous&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; system disorders</p></td><td style="vertical-align:top"><p>Somnolence, headache</p></td><td style="vertical-align:top"><p>Convulsion, balance disorder, dizziness, lethargy, tremor</p></td><td style="vertical-align:top"><p>Amnesia,&nbsp;&nbsp;&nbsp; memory impairment, coordination abnormal/ataxia, paraesthesia, disturbance&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in attention</p></td><td style="vertical-align:top"><p>Choreoathetosis, dyskinesia, hyperkinesia, gait disturbance, encephalopathy, seizures</p><p>aggravated</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Diplopia,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vision blurred</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Electrocardiogram QT prolonged</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>thoracic&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Abdominal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain, diarrhoea, dyspepsia, vomiting, nausea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Liver function test abnormal</p></td><td style="vertical-align:top"><p>Hepatic&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; failure, hepatitis</p></td></tr><tr><td style="vertical-align:top"><p>Skin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</p><p>subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Alopecia,&nbsp;&nbsp;&nbsp; eczema, pruritus,</p></td><td style="vertical-align:top"><p>Toxic&nbsp;&nbsp;&nbsp;&nbsp; epidermal necrolysis, Stevens-Johnson syndrome<sup>)</sup>, erythema multiforme</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscular weakness, myalgia</p></td><td style="vertical-align:top"><p>Rhabdomyolysis and blood creatine phosphokinase increased*</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Asthenia/fatigue</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Injury</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients.</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p>The risk of anorexia is higher when levetiracetam is coadministered with topiramate.</p><p>In several cases of alopecia, recovery was observed when levetiracetam was discontinued. Bone marrow suppression was identified in some of the cases of pancytopenia.</p><p>Cases of encephalopathy generally occurred at the beginning of the treatment (few days to a few months) and were reversible after treatment discontinuation.</p><p>Paediatric population</p><p>In patients aged 1 month to less than 4 years, a total of 190 patients have been treated with levetiracetam in placebocontrolled and open label extension studies. Sixty of these patients were treated with levetiracetam in placebo-controlled studies. In patients aged 4-16 years, a total of 645 patients have been treated with levetiracetam in placebo-controlled and open label extension studies. 233 of these patients were treated with levetiracetam in placebo-controlled studies. In both these paediatric age ranges, these data are supplemented with the post-marketing experience of the use of levetiracetam.</p><p>In addition, 101 infants aged less than 12 months have been exposed in a post authorization safety study. No new safety concerns for levetiracetam were identified for infants less than 12 months of age with epilepsy.</p><p>The adverse reaction profile of levetiracetam is generally similar across age groups and across the approved epilepsy indications. Safety results in paediatric patients in placebo-controlled clinical studies were consistent with the safety profile of levetiracetam in adults except for behavioural and psychiatric adverse reactions which were more common in children than in adults. In children and adolescents aged 4 to 16 years, vomiting (very common, 11.2%), agitation (common, 3.4%), mood swings (common, 2.1%), affect lability (common, 1.7%), aggression (common, 8.2%), abnormal behaviour (common, 5.6%), and lethargy (common, 3.9%) were reported more frequently than in other age ranges or in the overall safety profile. In infants and children aged 1 month to less than 4 years, irritability (very common, 11.7%) and coordination abnormal (common, 3.3%) were reported more frequently than in other age groups or in the overall safety</p><p>profile.</p><p>&nbsp;</p><p>A double-blind, placebo-controlled paediatric safety study with a non-inferiority design has assessed the cognitive and neuropsychological effects of levetiracetam in children 4 to 16 years of age with partial onset seizures. It was concluded that Racitam was not different (non inferior) from placebo with regard to the change from baseline of the Leiter-R Attention and Memory, Memory Screen Composite score in the per-protocol population. Results related to behavioural and emotional functioning indicated a worsening in levetiracetam treated patients on aggressive behaviour as measured in a standardised and systematic way using a validated instrument (CBCL &ndash; Achenbach Child Behavior Checklist).</p><p>However, subjects, who took levetiracetam in the long-term open label follow-up study, did not experience a worsening, on average, in their behavioural and emotional functioning; in particular measures of aggressive behaviour were not worse than baseline.</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions (see details below)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms</p><p>&nbsp;</p><p>Somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with Racitam overdoses.</p><p>Management of overdose</p><p>After an acute overdose, the stomach may be emptied by gastric lavage or by induction of emesis. There is no specific antidote for levetiracetam. Treatment of an overdose will be symptomatic and may include haemodialysis. The dialyser extraction efficiency is 60 % for levetiracetam and 74 % for the primary metabolite.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX14</p><p>The active substance, levetiracetam, is a pyrrolidone derivative (S-enantiomer of &alpha;-ethyl-2-oxo- 1-pyrrolidine acetamide), chemically unrelated to existing antiepileptic active substances.</p><p><u>Mechanism of action</u></p><p>The mechanism of action of levetiracetam still remains to be fully elucidated. In vitro and in vivo experiments suggest that levetiracetam does not alter basic cell characteristics and normal neurotransmission.</p><p>In vitro studies show that levetiracetam affects intraneuronal Ca2+ levels by partial inhibition of N-type Ca2+ currents and by reducing the release of Ca2+ from intraneuronal stores. In addition it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and &beta;- carbolines. Furthermore, levetiracetam has been shown in in vitro studies to bind to a specific site in rodent brain tissue. This binding site is the synaptic vesicle protein 2A, believed to be involved in vesicle fusion and neurotransmitter exocytosis. Levetiracetam and related analogs show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their anti-seizure protection in the mouse audiogenic model of epilepsy. This finding suggests that the interaction between levetiracetam and the synaptic vesicle protein 2A seems to contribute to the antiepileptic mechanism of action of the medicinal product.</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>Levetiracetam induces seizure protection in a broad range of animal models of partial and primary generalised seizures without having a pro-convulsant effect. The primary metabolite is inactive.</p><p>In man, an activity in both partial and generalised epilepsy conditions (epileptiform discharge/photoparoxysmal response) has confirmed the broad spectrum pharmacological profile of levetiracetam.</p><p><u>Clinical efficacy and safety</u></p><p>Adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy.</p><p>In adults, levetiracetam efficacy has been demonstrated in 3 double-blind, placebo-controlled studies at 1000 mg, 2000 mg, or 3000 mg/day, given in 2 divided doses, with a treatment duration of up to 18 weeks. In a pooled analysis, the percentage of patients who achieved 50% or greater reduction from baseline in the partial onset seizure frequency per week at stable dose (12/14 weeks) was of 27.7 %, 31.6 % and 41.3 % for patients on 1000, 2000 or 3000 mg levetiracetam respectively and of 12.6 % for patients on placebo.</p><p><u>Paediatric population</u></p><p>In paediatric patients (4 to 16 years of age), levetiracetam efficacy was established in a double- blind, placebo-controlled study, which included 198 patients and had a treatment duration of 14 weeks. In this study, the patients received levetiracetam as a fixed dose of 60 mg/kg/day (with twice a day dosing).</p><p>44.6 % of the levetiracetam treated patients and 19.6 % of the patients on placebo had a 50 % or greater reduction from baseline in the partial onset seizure frequency per week. With continued long-term treatment, 11.4 % of the patients were seizure-free for at least 6 months and 7.2 % were seizure-free for at least 1 year.</p><p>In paediatric patients (1 month to less than 4 years of age), levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 116 patients and had a treatment duration of 5 days. In this study, patients</p><p>were prescribed 20 mg/kg, 25 mg/kg, 40 mg/kg or 50 mg/kg daily dose of oral solution based on their age titration schedule. A dose of 20 mg/kg/day titrating to 40 mg/kg/day for infants one</p><p>&nbsp;</p><p>month to less than six months and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for infants and children 6 months to less than 4 years old, was use in this study.</p><p>The total daily dose was administered twice daily.</p><p>The primary measure of effectiveness was the responder rate (percent of patients with &ge; 50% reduction from baseline in average daily partial onset seizure frequency) assessed by a blinded central reader using a 48-hour video EEG. The efficacy analysis consisted of 109 patients who had at least 24 hours of video EEG in both baseline and evaluation periods. 43.6 % of the levetiracetam treated patients and 19.6 % of the patients on placebo were considered as responders. The results are consistent across age group. With continued long-term treatment, 8.6</p><p>% of the patients were seizure-free for at least 6 months and 7.8 % were seizure-free for at least 1 year.</p><p>35 infants aged less than 1 year with partial onset seizures have been exposed in placebo-control clinical studies of which only 13 were aged &lt; 6 months.</p><p>Monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.</p><p>Efficacy of levetiracetam as monotherapy was established in a double-blind, parallel group, non- inferiority comparison to carbamazepine-controlled release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy. The patients had to present with unprovoked partial seizures or with generalized tonic-clonic seizures only. The patients were randomized to carbamazepine CR 400 &ndash; 1200 mg/day or levetiracetam 1000 &ndash; 3000 mg/day, the duration</p><p>of the treatment was up to 121 weeks depending on the response.</p><p>Six-month seizure freedom was achieved in 73.0 % of levetiracetam-treated patients and 72.8 % of carbamazepine-CR treated patients; the adjusted absolute difference between treatments was 0.2% (95 % CI: -7.8 8.2). More than half of the subjects remained seizure free for 12 months (56.6 % and 58.5 % of subjects on levetiracetam and on carbamazepine CR respectively).</p><p>In a study reflecting clinical practice, the concomitant antiepileptic medication could be withdrawn in a limited number of patients who responded to levetiracetam adjunctive therapy (36 adult patients out of 69).</p><p>&nbsp;</p><p>Adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.</p><p>Levetiracetam efficacy was established in a double-blind, placebo-controlled study of 16 weeks duration, in patients 12 years of age and older suffering from idiopathic generalized epilepsy with myoclonic seizures in different syndromes.</p><p>The majority of patients presented with juvenile myoclonic epilepsy.</p><p>In this study, levetiracetam, dose was 3000 mg/day given in 2 divided doses.</p><p>58.3 % of the levetiracetam treated patients and 23.3 % of the patients on placebo had at least a 50 % reduction in myoclonic seizure days per week. With continued long-term treatment, 28.6 % of the patients were free of myoclonic seizures for at least 6 months and 21.0 % were free of myoclonic seizures for at least 1 year.</p><p>Adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.</p><p>Levetiracetam efficacy was established in a 24-week double-blind, placebo-controlled study which included adults, adolescents and a limited number of children suffering from idiopathic generalized epilepsy with primary generalized tonic-clonic (PGTC) seizures in different syndromes (juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening). In this study, levetiracetam dose was 3000 mg/day for adults and adolescents or 60 mg/kg/day for children, given in 2 divided doses.</p><p>72.2 % of the levetiracetam treated patients and 45.2 % of the patients on placebo had a 50 % or greater decrease in the frequency of PGTC seizures per week. With continued long-term treatment, 47.4 % of the patients were free of tonicclonic seizures for at least 6 months and 31.5</p><p>% were free of tonic-clonic seizures for at least 1 year.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levetiracetam is a highly soluble and permeable compound. The pharmacokinetic profile is linear with low intra- and inter-subject variability. There is no modification of the clearance after repeated administration. There is no evidence for any relevant gender, race or circadian variability. The pharmacokinetic profile is comparable in healthy volunteers and in patients with epilepsy.</p><p>&nbsp;</p><p>Due to its complete and linear absorption, plasma levels can be predicted from the oral dose of levetiracetam expressed as mg/kg bodyweight. Therefore, there is no need for plasma level monitoring of levetiracetam.</p><p>A significant correlation between saliva and plasma concentrations has been shown in adults and children (ratio of saliva/plasma concentrations ranged from 1 to 1.7 for oral tablet formulation and after 4 hours post-dose for oral solution formulation).</p><p>Adults and adolescents <u>Absorption</u></p><p>Levetiracetam is rapidly absorbed after oral administration. Oral absolute bioavailability is close to 100 %. Peak plasma concentrations (Cmax) are achieved at 1.3 hours after dosing. Steady- state is achieved after two days of a twice daily administration schedule.</p><p>Peak concentrations (Cmax) are typically 31 and 43 &mu;g/ml following a single 1,000 mg dose and repeated 1,000 mg twice daily dose, respectively. The extent of absorption is dose-independent and is not altered by food.</p><p><u>Distribution</u></p><p>No tissue distribution data are available in humans.</p><p>Neither levetiracetam nor its primary metabolite are significantly bound to plasma proteins (&lt; 10</p><p>%).</p><p>The volume of distribution of levetiracetam is approximately 0.5 to 0.7 l/kg, a value close to the total body water volume.</p><p><u>Biotransformation</u></p><p>Levetiracetam is not extensively metabolised in humans. The major metabolic pathway (24 % of the dose) is an enzymatic hydrolysis of the acetamide group. Production of the primary metabolite, ucb L057, is not supported by liver cytochrome P450 isoforms. Hydrolysis of the acetamide group was measurable in a large number of tissues including blood cells. The metabolite ucb L057 is pharmacologically inactive.</p><p>Two minor metabolites were also identified. One was obtained by hydroxylation of the pyrrolidone ring (1.6 % of the dose) and the other one by opening of the pyrrolidone ring (0.9 % of the dose).</p><p>&nbsp;</p><p>Other unidentified components accounted only for 0.6 % of the dose.</p><p>No enantiomeric interconversion was evidenced in vivo for either levetiracetam or its primary metabolite.</p><p>In vitro, levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P450 isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2), glucuronyl transferase (UGT1A1 and UGT1A6) and epoxide hydroxylase activities. In addition, levetiracetam does not affect the in vitro glucuronidation of valproic acid.</p><p>In human hepatocytes in culture, levetiracetam had little or no effect on CYP1A2, SULT1E1 or UGT1A1. Levetiracetam caused mild induction of CYP2B6 and CYP3A4. The in vitro data and in vivo interaction data on oral contraceptives, digoxin and warfarin indicate that no significant enzyme induction is expected in vivo. Therefore, the interaction of Levetiracetam with other substances, or vice versa, is unlikely.</p><p><u>Elimination</u></p><p>The plasma half-life in adults was 7&plusmn;1 hours and did not vary either with dose, route of administration or repeated administration. The mean total body clearance was 0.96 ml/min/kg.</p><p>The major route of excretion was via urine, accounting for a mean 95 % of the dose (approximately 93 % of the dose was excreted within 48 hours). Excretion via faeces accounted for only 0.3 % of the dose.</p><p>The cumulative urinary excretion of levetiracetam and its primary metabolite accounted for 66 % and 24 % of the dose, respectively during the first 48 hours.</p><p>The renal clearance of levetiracetam and ucb L057 is 0.6 and 4.2 ml/min/kg respectively indicating that levetiracetam is excreted by glomerular filtration with subsequent tubular reabsorption and that the primary metabolite is also excreted by active tubular secretion in addition to glomerular filtration. Levetiracetam elimination is correlated to creatinine clearance. <u>Elderly</u></p><p>In the elderly, the half-life is increased by about 40 % (10 to 11 hours). This is related to the decrease in renal function in this population (see section 4.2).</p><p><u>Renal impairment</u></p><p>&nbsp;</p><p>The apparent body clearance of both levetiracetam and of its primary metabolite is correlated to the creatinine clearance. It is therefore recommended to adjust the maintenance daily dose of Racitam, based on creatinine clearance in patients with moderate and severe renal impairment (see section 4.2).</p><p>In anuric end-stage renal disease adult subjects the half-life was approximately 25 and 3.1 hours during interdialytic and intradialytic periods, respectively.</p><p>The fractional removal of levetiracetam was 51 % during a typical 4-hour dialysis session. <u>Hepatic impairment</u></p><p>In subjects with mild and moderate hepatic impairment, there was no relevant modification of the clearance of levetiracetam. In most subjects with severe hepatic impairment, the clearance of levetiracetam was reduced by more than 50 % due to a concomitant renal impairment (see section 4.2).</p><p><u>Paediatric population</u> <u>Children (4 to 12 years)</u></p><p>Following single oral dose administration (20 mg/kg) to epileptic children (6 to 12 years), the half-life of levetiracetam was 6.0 hours. The apparent body weight adjusted clearance was approximately 30 % higher than in epileptic adults.</p><p>Following repeated oral dose administration (20 to 60 mg/kg/day) to epileptic children (4 to 12 years), levetiracetam was rapidly absorbed. Peak plasma concentration was observed 0.5 to 1.0 hour after dosing. Linear and dose proportional increases were observed for peak plasma concentrations and area under the curve. The elimination half-life was approximately 5 hours. The apparent body clearance was 1.1 ml/min/kg.</p><p><u>Infants and children (1 month to 4 years)</u></p><p>Following single dose administration (20 mg/kg) of a 100 mg/ml oral solution to epileptic children (1 month to 4 years), levetiracetam was rapidly absorbed and peak plasma concentrations were observed approximately 1 hour after dosing.</p><p>The pharmacokinetic results indicated that half-life was shorter (5.3 h) than for adults (7.2 h) and apparent clearance was faster (1.5 ml/min/kg) than for adults (0.96 ml/min/kg).</p><p>&nbsp;</p><p>In the population pharmacokinetic analysis conducted in patients from 1 month to 16 years of age, body weight was significantly correlated to apparent clearance (clearance increased with an increase in body weight) and apparent volume of distribution. Age also had an influence on both parameters. This effect was pronounced for the younger infants, and subsided as age increased, to become negligible around 4 years of age.</p><p>In both population pharmacokinetic analyses, there was about a 20 % increase of apparent clearance of levetiracetam when it was co-administered with an enzyme-inducing antiepileptic medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity and carcinogenic potential.</p><p>Adverse effects not observed in clinical studies but seen in the rat and to a lesser extent in the mouse at exposure levels similar to human exposure levels and with possible relevance for clinical use were liver changes, indicating an adaptive response such as increased weight and centrilobular hypertrophy, fatty infiltration and increased liver enzymes in plasma.</p><p>No adverse reactions on male or female fertility or reproduction performance were observed in rats at doses up to 1800 mg/kg/day (x 6 the MRHD on a mg/m2 or exposure basis) in parents and F1 generation.</p><p>Two embryo-foetal development (EFD) studies were performed in rats at 400, 1200 and 3600 mg/kg/day. At 3600 mg/kg/day, in only one of the 2 EFD studies, there was a slight decrease in foetal weight associated with a marginal increase in skeletal variations/minor anomalies. There was no effect on embryomortality and no increased incidence of malformations. The NOAEL (No Observed Adverse Effect Level) was 3600 mg/kg/day for pregnant female rats (x 12 the MRHD on a mg/m2 basis) and 1200 mg/kg/day for fetuses.</p><p>Four embryo-foetal development studies were performed in rabbits covering doses of 200, 600, 800, 1200 and 1800 mg/kg/day. The dose level of 1800 mg/kg/day induced a marked maternal toxicity and a decrease in foetal weight associated with increased incidence of fetuses with cardiovascular/skeletal anomalies. The NOAEL was &lt;200 mg/kg/day for the dams and 200 mg/kg/day for the fetuses (equal to the MRHD on a mg/m2 basis).</p><p>&nbsp;</p><p>A peri- and post-natal development study was performed in rats with levetiracetam doses of 70, 350 and 1800 mg/kg/day. The NOAEL was &ge; 1800 mg/kg/day for the F0 females, and for the survival, growth and development of the F1 offspring up to weaning (x 6 the MRHD on a mg/m2 basis).</p><p>Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1800 mg/kg/day (x 6- 17 the MRHD on a mg/m2 basis)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Racitam (Racitam 100mg/mL)</strong></p><p>The other ingredients are: Maltitol Liquid, Glycerol, Methyl Parahydroxy benzoate, Propyl Parahydroxy benzoate, Citric acid monohydrate, Sodium citrate, Glycyrrhizinate Ammonium, Acesulfame Potassium, ART Grape FL #10273, Purified Water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months
After first opening: 7 months

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>200mL Amber colour glass bottle (The 200 ml glass bottle, containing 150 ml of Racitam for infants and young children aged 6 months to less than 4 years), is packed in a cardboard box containing a 3 ml oral syringe (graduated from 1 ml to 3 ml) and an adaptor for the syringe.)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Amarox Industrial Company, Aljameah Street, Malaz quarter, Riyadh 11441, Saudi Arabia
Tel: +966 11 477 2215
 
Manufacture: Hetero Lab Unit III, Hyderabad, India

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May - 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>